Skip to main content
PMC home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1992 Apr;5(2):146–182. doi: 10.1128/cmr.5.2.146

Antiviral therapy: current concepts and practices.

B Bean 1
PMCID: PMC358233  PMID: 1576586

Abstract

Drugs capable of inhibiting viruses in vitro were described in the 1950s, but real progress was not made until the 1970s, when agents capable of inhibiting virus-specific enzymes were first identified. The last decade has seen rapid progress in both our understanding of antiviral therapy and the number of antiviral agents on the market. Amantadine and ribavirin are available for treatment of viral respiratory infections. Vidarabine, acyclovir, ganciclovir, and foscarnet are used for systemic treatment of herpesvirus infections, while ophthalmic preparations of idoxuridine, trifluorothymidine, and vidarabine are available for herpes keratitis. For treatment of human immunodeficiency virus infections, zidovudine and didanosine are used. Immunomodulators, such as interferons and colony-stimulating factors, and immunoglobulins are being used increasingly for viral illnesses. While resistance to antiviral drugs has been seen, especially among AIDS patients, it has not become widespread and is being intensely studied. Increasingly, combinations of agents are being used: to achieve synergistic inhibition of viruses, to delay or prevent resistance, and to decrease dosages of toxic drugs. New approaches, such as liposomes carrying antiviral drugs and computer-aided drug design, are exciting and promising prospects for the future.

Full text

PDF
146

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia G., Cooney D. A., Mitsuya H., Fridland A., Flora K. P., Hao Z., Dalal M., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987 Nov 15;36(22):3797–3800. doi: 10.1016/0006-2952(87)90440-0. [DOI] [PubMed] [Google Scholar]
  2. Andersson J., Britton S., Ernberg I., Andersson U., Henle W., Sköldenberg B., Tisell A. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis. 1986 Feb;153(2):283–290. doi: 10.1093/infdis/153.2.283. [DOI] [PubMed] [Google Scholar]
  3. Apperley J. F., Marcus R. E., Goldman J. M., Wardle D. G., Gravett P. J., Chanas A. Foscarnet for cytomegalovirus pneumonitis. Lancet. 1985 May 18;1(8438):1151–1151. doi: 10.1016/s0140-6736(85)92447-x. [DOI] [PubMed] [Google Scholar]
  4. Arvin A. M., Kushner J. H., Feldman S., Baehner R. L., Hammond D., Merigan T. C. Human leukocyte interferon for the treatment of varicella in children with cancer. N Engl J Med. 1982 Apr 1;306(13):761–765. doi: 10.1056/NEJM198204013061301. [DOI] [PubMed] [Google Scholar]
  5. Ashorn P., Moss B., Weinstein J. N., Chaudhary V. K., FitzGerald D. J., Pastan I., Berger E. A. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8889–8893. doi: 10.1073/pnas.87.22.8889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Avramis V. I., Markson W., Jackson R. L., Gomperts E. Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM). AIDS. 1989 Jul;3(7):417–422. doi: 10.1097/00002030-198907000-00002. [DOI] [PubMed] [Google Scholar]
  7. Aweeka F., Gambertoglio J., Mills J., Jacobson M. A. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989 May;33(5):742–745. doi: 10.1128/aac.33.5.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. BAUER D. J., STVINCENT L., KEMPE C. H., DOWNIE A. W. PROPHYLACTIC TREATMENT OF SMALL POX CONTACTS WITH N-METHYLISATIN BETA-THIOSEMICARBAZONE (COMPOUND 33T57, MARBORAN). Lancet. 1963 Sep 7;2(7306):494–496. doi: 10.1016/s0140-6736(63)90230-7. [DOI] [PubMed] [Google Scholar]
  9. BRINK J. J., LEPAGE G. A. METABOLIC EFFECTS OF 9-D-ARABINOSYLPURINES IN ASCITES TUMOR CELLS. Cancer Res. 1964 Feb;24:312–318. [PubMed] [Google Scholar]
  10. Baba M., De Clercq E., Iida S., Tanaka H., Nitta I., Ubasawa M., Takashima H., Sekiya K., Umezu K., Nakashima H. Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives. Antimicrob Agents Chemother. 1990 Dec;34(12):2358–2363. doi: 10.1128/aac.34.12.2358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Baba M., Pauwels R., Balzarini J., Herdewijn P., De Clercq E., Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 1987 Oct;31(10):1613–1617. doi: 10.1128/aac.31.10.1613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Baba M., Tanaka H., De Clercq E., Pauwels R., Balzarini J., Schols D., Nakashima H., Perno C. F., Walker R. T., Miyasaka T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1375–1381. doi: 10.1016/0006-291x(89)92756-3. [DOI] [PubMed] [Google Scholar]
  13. Baldwin G. C., Gasson J. C., Quan S. G., Fleischmann J., Weisbart R., Oette D., Mitsuyasu R. T., Golde D. W. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2763–2766. doi: 10.1073/pnas.85.8.2763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Balfour H. H., Jr, Bean B., Laskin O. L., Ambinder R. F., Meyers J. D., Wade J. C., Zaia J. A., Aeppli D., Kirk L. E., Segreti A. C. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983 Jun 16;308(24):1448–1453. doi: 10.1056/NEJM198306163082404. [DOI] [PubMed] [Google Scholar]
  15. Balfour H. H., Jr, Bean B., Mitchell C. D., Sachs G. W., Boen J. R., Edelman C. K. Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution. Am J Med. 1982 Jul 20;73(1A):241–248. doi: 10.1016/0002-9343(82)90099-7. [DOI] [PubMed] [Google Scholar]
  16. Balfour H. H., Jr, Chace B. A., Stapleton J. T., Simmons R. L., Fryd D. S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989 May 25;320(21):1381–1387. doi: 10.1056/NEJM198905253202105. [DOI] [PubMed] [Google Scholar]
  17. Balfour H. H., Jr, Kelly J. M., Suarez C. S., Heussner R. C., Englund J. A., Crane D. D., McGuirt P. V., Clemmer A. F., Aeppli D. M. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr. 1990 Apr;116(4):633–639. doi: 10.1016/s0022-3476(05)81618-x. [DOI] [PubMed] [Google Scholar]
  18. Barry D. W., Nusinoff-Lehrman S., Ellis M. N., Biron K. K., Furman P. A. Viral resistance, clinical experience. Scand J Infect Dis Suppl. 1985;47:155–164. [PubMed] [Google Scholar]
  19. Beall G., Kruger S., Morales F., Imagawa D., Goldsmith J. A., Fisher D., Steinberg J., Phair J., Whaling S., Bitran J. A double-blind, placebo-controlled trial of thymostimulin in symptomatic HIV-infected patients. AIDS. 1990 Jul;4(7):679–681. doi: 10.1097/00002030-199007000-00012. [DOI] [PubMed] [Google Scholar]
  20. Bean B., Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis. 1985 Feb;151(2):362–365. doi: 10.1093/infdis/151.2.362. [DOI] [PubMed] [Google Scholar]
  21. Bean B., Braun C., Balfour H. H., Jr Acyclovir therapy for acute herpes zoster. Lancet. 1982 Jul 17;2(8290):118–121. doi: 10.1016/s0140-6736(82)91090-x. [DOI] [PubMed] [Google Scholar]
  22. Bean B., Fletcher C., Englund J., Lehrman S. N., Ellis M. N. Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. Diagn Microbiol Infect Dis. 1987 Jul;7(3):199–204. doi: 10.1016/0732-8893(87)90005-8. [DOI] [PubMed] [Google Scholar]
  23. Bean W. J., Threlkeld S. C., Webster R. G. Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis. 1989 Jun;159(6):1050–1056. doi: 10.1093/infdis/159.6.1050. [DOI] [PubMed] [Google Scholar]
  24. Beasley R. P., Hwang L. Y., Lin C. C., Stevens C. E., Wang K. Y., Sun T. S., Hsieh F. J., Szmuness W. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet. 1981 Aug 22;2(8243):388–393. doi: 10.1016/s0140-6736(81)90832-1. [DOI] [PubMed] [Google Scholar]
  25. Belshe R. B., Burk B., Newman F., Cerruti R. L., Sim I. S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis. 1989 Mar;159(3):430–435. doi: 10.1093/infdis/159.3.430. [DOI] [PubMed] [Google Scholar]
  26. Belshe R. B., Smith M. H., Hall C. B., Betts R., Hay A. J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol. 1988 May;62(5):1508–1512. doi: 10.1128/jvi.62.5.1508-1512.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Bergdahl S., Sönnerborg A., Larsson A., Strannegard O. Declining levels of HIV P24 antigen in serum during treatment with foscarnet. Lancet. 1988 May 7;1(8593):1052–1052. doi: 10.1016/s0140-6736(88)91867-3. [DOI] [PubMed] [Google Scholar]
  28. Berglund O., Engman K., Ehrnst A., Andersson J., Lidman K., Akerlund B., Sönnerborg A., Strannegård O. Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine. J Infect Dis. 1991 Apr;163(4):710–715. doi: 10.1093/infdis/163.4.710. [DOI] [PubMed] [Google Scholar]
  29. Berkman S. A., Lee M. L., Gale R. P. Clinical uses of intravenous immunoglobulins. Ann Intern Med. 1990 Feb 15;112(4):278–292. doi: 10.7326/0003-4819-112-4-278. [DOI] [PubMed] [Google Scholar]
  30. Bernstein D. I., Reuman P. D., Sherwood J. R., Young E. C., Schiff G. M. Ribavirin small-particle-aerosol treatment of influenza B virus infection. Antimicrob Agents Chemother. 1988 May;32(5):761–764. doi: 10.1128/aac.32.5.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Birch C. J., Tachedjian G., Doherty R. R., Hayes K., Gust I. D. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis. 1990 Sep;162(3):731–734. doi: 10.1093/infdis/162.3.731. [DOI] [PubMed] [Google Scholar]
  32. Biron K. K., Elion G. B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980 Sep;18(3):443–447. doi: 10.1128/aac.18.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Biron K. K., Fyfe J. A., Stanat S. C., Leslie L. K., Sorrell J. B., Lambe C. U., Coen D. M. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8769–8773. doi: 10.1073/pnas.83.22.8769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Biron K. K., Stanat S. C., Sorrell J. B., Fyfe J. A., Keller P. M., Lambe C. U., Nelson D. J. Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2473–2477. doi: 10.1073/pnas.82.8.2473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Blum M. R., Liao S. H., Good S. S., de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988 Aug 29;85(2A):189–194. [PubMed] [Google Scholar]
  36. Bodsworth N., Cooper D. A. Ribavirin: a role in HIV infection? J Acquir Immune Defic Syndr. 1990;3(9):893–895. [PubMed] [Google Scholar]
  37. Bowden R. A., Fisher L. D., Rogers K., Cays M., Meyers J. D. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis. 1991 Sep;164(3):483–487. doi: 10.1093/infdis/164.3.483. [DOI] [PubMed] [Google Scholar]
  38. Bowden R. A., Sayers M., Flournoy N., Newton B., Banaji M., Thomas E. D., Meyers J. D. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986 Apr 17;314(16):1006–1010. doi: 10.1056/NEJM198604173141602. [DOI] [PubMed] [Google Scholar]
  39. Bozzette S. A., Richman D. D. Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine. Am J Med. 1990 May 21;88(5B):24S–26S. doi: 10.1016/0002-9343(90)90418-d. [DOI] [PubMed] [Google Scholar]
  40. Brown Z. A., Baker D. A. Acyclovir therapy during pregnancy. Obstet Gynecol. 1989 Mar;73(3 Pt 2):526–531. [PubMed] [Google Scholar]
  41. Bryson Y. J., Dillon M., Lovett M., Acuna G., Taylor S., Cherry J. D., Johnson B. L., Wiesmeier E., Growdon W., Creagh-Kirk T. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983 Apr 21;308(16):916–921. doi: 10.1056/NEJM198304213081602. [DOI] [PubMed] [Google Scholar]
  42. Buhles W. C., Jr, Mastre B. J., Tinker A. J., Strand V., Koretz S. H. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 3):S495–S506. doi: 10.1093/clinids/10.supplement_3.s495. [DOI] [PubMed] [Google Scholar]
  43. Bukrinskaya A. G., Vorkunova N. K., Narmanbetova R. A. Rimantadine hydrochloride blocks the second step of influenza virus uncoating. Arch Virol. 1980;66(3):275–282. doi: 10.1007/BF01314742. [DOI] [PubMed] [Google Scholar]
  44. Burns W. H., Saral R., Santos G. W., Laskin O. L., Lietman P. S., McLaren C., Barry D. W. Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet. 1982 Feb 20;1(8269):421–423. doi: 10.1016/s0140-6736(82)91620-8. [DOI] [PubMed] [Google Scholar]
  45. Butler K. M., Husson R. N., Balis F. M., Brouwers P., Eddy J., el-Amin D., Gress J., Hawkins M., Jarosinski P., Moss H. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991 Jan 17;324(3):137–144. doi: 10.1056/NEJM199101173240301. [DOI] [PubMed] [Google Scholar]
  46. Byrn R. A., Mordenti J., Lucas C., Smith D., Marsters S. A., Johnson J. S., Cossum P., Chamow S. M., Wurm F. M., Gregory T. Biological properties of a CD4 immunoadhesin. Nature. 1990 Apr 12;344(6267):667–670. doi: 10.1038/344667a0. [DOI] [PubMed] [Google Scholar]
  47. Camaioni Neto C., Steim J. M., Sarin P. S., Sun D. K., Bhongle N. N., Piratla R. K., Turcotte J. G. Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins. Biochem Biophys Res Commun. 1990 Aug 31;171(1):458–464. doi: 10.1016/0006-291x(90)91415-o. [DOI] [PubMed] [Google Scholar]
  48. Capon D. J., Chamow S. M., Mordenti J., Marsters S. A., Gregory T., Mitsuya H., Byrn R. A., Lucas C., Wurm F. M., Groopman J. E. Designing CD4 immunoadhesins for AIDS therapy. Nature. 1989 Feb 9;337(6207):525–531. doi: 10.1038/337525a0. [DOI] [PubMed] [Google Scholar]
  49. Cassidy L. F., Patterson J. L. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother. 1989 Nov;33(11):2009–2011. doi: 10.1128/aac.33.11.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Chachoua A., Dieterich D., Krasinski K., Greene J., Laubenstein L., Wernz J., Buhles W., Koretz S. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann Intern Med. 1987 Aug;107(2):133–137. doi: 10.7326/0003-4819-107-2-133. [DOI] [PubMed] [Google Scholar]
  51. Chatis P. A., Miller C. H., Schrager L. E., Crumpacker C. S. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):297–300. doi: 10.1056/NEJM198902023200507. [DOI] [PubMed] [Google Scholar]
  52. Chaudhary V. K., Mizukami T., Fuerst T. R., FitzGerald D. J., Moss B., Pastan I., Berger E. A. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature. 1988 Sep 22;335(6188):369–372. doi: 10.1038/335369a0. [DOI] [PubMed] [Google Scholar]
  53. Cheng Y. C., Dutschman G. E., Bastow K. F., Sarngadharan M. G., Ting R. Y. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem. 1987 Feb 15;262(5):2187–2189. [PubMed] [Google Scholar]
  54. Cheng Y. C., Grill S. P., Dutschman G. E., Nakayama K., Bastow K. F. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem. 1983 Oct 25;258(20):12460–12464. [PubMed] [Google Scholar]
  55. Chu C. K., Schinazi R. F., Ahn M. K., Ullas G. V., Gu Z. P. Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells. J Med Chem. 1989 Mar;32(3):612–617. doi: 10.1021/jm00123a018. [DOI] [PubMed] [Google Scholar]
  56. Clover R. D., Crawford S. A., Abell T. D., Ramsey C. N., Jr, Glezen W. P., Couch R. B. Effectiveness of rimantadine prophylaxis of children within families. Am J Dis Child. 1986 Jul;140(7):706–709. doi: 10.1001/archpedi.1986.02140210104036. [DOI] [PubMed] [Google Scholar]
  57. Cobo L. M., Foulks G. N., Liesegang T., Lass J., Sutphin J. E., Wilhelmus K., Jones D. B., Chapman S., Segreti A. C., King D. H. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986 Jun;93(6):763–770. doi: 10.1016/s0161-6420(86)33678-9. [DOI] [PubMed] [Google Scholar]
  58. Cobo L. M., Foulks G. N., Liesegang T., Lass J., Sutphin J., Wilhelmus K., Jones D. B., Chapman S., Segreti A. Oral acyclovir in the therapy of acute herpes zoster ophthalmicus. An interim report. Ophthalmology. 1985 Nov;92(11):1574–1583. doi: 10.1016/s0161-6420(85)33842-3. [DOI] [PubMed] [Google Scholar]
  59. Coen D. M. General aspects of virus drug resistance with special reference to herpes simplex virus. J Antimicrob Chemother. 1986 Oct;18 (Suppl B):1–10. doi: 10.1093/jac/18.supplement_b.1. [DOI] [PubMed] [Google Scholar]
  60. Coen D. M., Schaffer P. A. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2265–2269. doi: 10.1073/pnas.77.4.2265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Colby B. M., Shaw J. E., Elion G. B., Pagano J. S. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol. 1980 May;34(2):560–568. doi: 10.1128/jvi.34.2.560-568.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Collier A. C., Bozzette S., Coombs R. W., Causey D. M., Schoenfeld D. A., Spector S. A., Pettinelli C. B., Davies G., Richman D. D., Leedom J. M. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med. 1990 Oct 11;323(15):1015–1021. doi: 10.1056/NEJM199010113231502. [DOI] [PubMed] [Google Scholar]
  63. Collins P., Larder B. A., Oliver N. M., Kemp S., Smith I. W., Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol. 1989 Feb;70(Pt 2):375–382. doi: 10.1099/0022-1317-70-2-375. [DOI] [PubMed] [Google Scholar]
  64. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCaffrey R. P., Liebman H. A. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med. 1990 May 10;322(19):1340–1345. doi: 10.1056/NEJM199005103221902. [DOI] [PubMed] [Google Scholar]
  65. Cooney D. A., Ahluwalia G., Mitsuya H., Fridland A., Johnson M., Hao Z., Dalal M., Balzarini J., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol. 1987 Jun 1;36(11):1765–1768. doi: 10.1016/0006-2952(87)90235-8. [DOI] [PubMed] [Google Scholar]
  66. Corey L., Benedetti J., Critchlow C., Mertz G., Douglas J., Fife K., Fahnlander A., Remington M. L., Winter C., Dragavon J. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):79–88. doi: 10.1093/jac/12.suppl_b.79. [DOI] [PubMed] [Google Scholar]
  67. Corey L., Nahmias A. J., Guinan M. E., Benedetti J. K., Critchlow C. W., Holmes K. K. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med. 1982 Jun 3;306(22):1313–1319. doi: 10.1056/NEJM198206033062201. [DOI] [PubMed] [Google Scholar]
  68. Creagh-Kirk T., Doi P., Andrews E., Nusinoff-Lehrman S., Tilson H., Hoth D., Barry D. W. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA. 1988 Nov 25;260(20):3009–3015. [PubMed] [Google Scholar]
  69. Crumpacker C. S., Kowalsky P. N., Oliver S. A., Schnipper L. E., Field A. K. Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1556–1560. doi: 10.1073/pnas.81.5.1556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Crumpacker C. S., Schnipper L. E., Marlowe S. I., Kowalsky P. N., Hershey B. J., Levin M. J. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982 Feb 11;306(6):343–346. doi: 10.1056/NEJM198202113060606. [DOI] [PubMed] [Google Scholar]
  71. Crumpacker C. S., Schnipper L. E., Zaia J. A., Levin M. J. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother. 1979 May;15(5):642–645. doi: 10.1128/aac.15.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Crumpacker C., Bubley G., Lucey D., Hussey S., Connor J. Ribavirin enters cerebrospinal fluid. Lancet. 1986 Jul 5;2(8497):45–46. doi: 10.1016/s0140-6736(86)92590-0. [DOI] [PubMed] [Google Scholar]
  73. Crumpacker C., Marlowe S., Zhang J. L., Abrams S., Watkins P. Treatment of cytomegalovirus pneumonia. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 3):S538–S546. doi: 10.1093/clinids/10.supplement_3.s538. [DOI] [PubMed] [Google Scholar]
  74. Cudd A., Noonan C. A., Tosi P. F., Melnick J. L., Nicolau C. Specific interaction of CD4-bearing liposomes with HIV-infected cells. J Acquir Immune Defic Syndr. 1990;3(2):109–114. [PubMed] [Google Scholar]
  75. Dalakas M. C., Illa I., Pezeshkpour G. H., Laukaitis J. P., Cohen B., Griffin J. L. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990 Apr 19;322(16):1098–1105. doi: 10.1056/NEJM199004193221602. [DOI] [PubMed] [Google Scholar]
  76. Daniels R. S., Downie J. C., Hay A. J., Knossow M., Skehel J. J., Wang M. L., Wiley D. C. Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell. 1985 Feb;40(2):431–439. doi: 10.1016/0092-8674(85)90157-6. [DOI] [PubMed] [Google Scholar]
  77. Darby G., Field H. J., Salisbury S. A. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981 Jan 1;289(5793):81–83. doi: 10.1038/289081a0. [DOI] [PubMed] [Google Scholar]
  78. Datta A. K., Colby B. M., Shaw J. E., Pagano J. S. Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5163–5166. doi: 10.1073/pnas.77.9.5163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Davey R. T., Jr, Davey V. J., Metcalf J. A., Zurlo J. J., Kovacs J. A., Falloon J., Polis M. A., Zunich K. M., Masur H., Lane H. C. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis. 1991 Jul;164(1):43–52. doi: 10.1093/infdis/164.1.43. [DOI] [PubMed] [Google Scholar]
  80. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  81. Davis G. L., Hoofnagle J. H. Interferon in viral hepatitis: role in pathogenesis and treatment. Hepatology. 1986 Sep-Oct;6(5):1038–1041. doi: 10.1002/hep.1840060537. [DOI] [PubMed] [Google Scholar]
  82. Davis M. G., Kenney S. C., Kamine J., Pagano J. S., Huang E. S. Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8642–8646. doi: 10.1073/pnas.84.23.8642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. De Clercq E. Basic approaches to anti-retroviral treatment. J Acquir Immune Defic Syndr. 1991;4(3):207–218. [PubMed] [Google Scholar]
  84. De Clercq E., Cools M., Balzarini J., Snoeck R., Andrei G., Hosoya M., Shigeta S., Ueda T., Minakawa N., Matsuda A. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds. Antimicrob Agents Chemother. 1991 Apr;35(4):679–684. doi: 10.1128/aac.35.4.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  86. DeArmond B. Future directions in the management of cytomegalovirus infections. J Acquir Immune Defic Syndr. 1991;4 (Suppl 1):S53–S56. [PubMed] [Google Scholar]
  87. Deray G., Martinez F., Katlama C., Levaltier B., Beaufils H., Danis M., Rozenheim M., Baumelou A., Dohin E., Gentilini M. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989;9(4):316–321. doi: 10.1159/000167987. [DOI] [PubMed] [Google Scholar]
  88. Derse D., Bastow K. F., Cheng Y. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid. J Biol Chem. 1982 Sep 10;257(17):10251–10260. [PubMed] [Google Scholar]
  89. Derse D., Cheng Y. C., Furman P. A., St Clair M. H., Elion G. B. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem. 1981 Nov 25;256(22):11447–11451. [PubMed] [Google Scholar]
  90. DesJarlais R. L., Seibel G. L., Kuntz I. D., Furth P. S., Alvarez J. C., Ortiz de Montellano P. R., DeCamp D. L., Babé L. M., Craik C. S. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6644–6648. doi: 10.1073/pnas.87.17.6644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Di Bisceglie A. M., Hoofnagle J. H. Therapy of chronic hepatitis C with alpha-interferon: the answer? Or more questions? Hepatology. 1991 Mar;13(3):601–603. doi: 10.1016/0270-9139(91)90318-p. [DOI] [PubMed] [Google Scholar]
  92. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  93. Dicioccio R. A., Srivastava B. I. Kinetics of inhibition of deoxynucleotide-polymerizing enzyme activities from normal and leukemic human cells by 9-beta-D-arabinofuranosyladenine 5'-triphosphate and 1-beta-D-arabinofuranosylcytosine 5'-triphosphate. Eur J Biochem. 1977 Oct 3;79(2):411–418. doi: 10.1111/j.1432-1033.1977.tb11823.x. [DOI] [PubMed] [Google Scholar]
  94. Dieterich D. T., Chachoua A., Lafleur F., Worrell C. Ganciclovir treatment of gastrointestinal infections caused by cytomegalovirus in patients with AIDS. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 3):S532–S537. doi: 10.1093/clinids/10.supplement_3.s532. [DOI] [PubMed] [Google Scholar]
  95. Dolin R., Reichman R. C., Madore H. P., Maynard R., Linton P. N., Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982 Sep 2;307(10):580–584. doi: 10.1056/NEJM198209023071002. [DOI] [PubMed] [Google Scholar]
  96. Dornsife R. E., St Clair M. H., Huang A. T., Panella T. J., Koszalka G. W., Burns C. L., Averett D. R. Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother. 1991 Feb;35(2):322–328. doi: 10.1128/aac.35.2.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Douglas J. M., Critchlow C., Benedetti J., Mertz G. J., Connor J. D., Hintz M. A., Fahnlander A., Remington M., Winter C., Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984 Jun 14;310(24):1551–1556. doi: 10.1056/NEJM198406143102402. [DOI] [PubMed] [Google Scholar]
  98. Douglas J. M., Jr, Eron L. J., Judson F. N., Rogers M., Alder M. B., Taylor E., Tanner D., Peets E. A randomized trial of combination therapy with intralesional interferon alpha 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis. 1990 Jul;162(1):52–59. doi: 10.1093/infdis/162.1.52. [DOI] [PubMed] [Google Scholar]
  99. Douglas R. G., Jr Prophylaxis and treatment of influenza. N Engl J Med. 1990 Feb 15;322(7):443–450. doi: 10.1056/NEJM199002153220706. [DOI] [PubMed] [Google Scholar]
  100. Douglas R. M., Moore B. W., Miles H. B., Davies L. M., Graham N. M., Ryan P., Worswick D. A., Albrecht J. K. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986 Jan 9;314(2):65–70. doi: 10.1056/NEJM198601093140201. [DOI] [PubMed] [Google Scholar]
  101. Dournon E., Matheron S., Rozenbaum W., Gharakhanian S., Michon C., Girard P. M., Perronne C., Salmon D., De Truchis P., Leport C. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet. 1988 Dec 3;2(8623):1297–1302. doi: 10.1016/s0140-6736(88)92903-0. [DOI] [PubMed] [Google Scholar]
  102. Drew W. L., Miner R. C., Busch D. F., Follansbee S. E., Gullett J., Mehalko S. G., Gordon S. M., Owen W. F., Jr, Matthews T. R., Buhles W. C. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991 Apr;163(4):716–719. doi: 10.1093/infdis/163.4.716. [DOI] [PubMed] [Google Scholar]
  103. Dunn D. L., Mayoral J. L., Gillingham K. J., Loeffler C. M., Brayman K. L., Kramer M. A., Erice A., Balfour H. H., Jr, Fletcher C. V., Bolman R. M., 3rd Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation. 1991 Jan;51(1):98–106. doi: 10.1097/00007890-199101000-00015. [DOI] [PubMed] [Google Scholar]
  104. Dwyer J. M., Erlendsson K. Intraventricular gamma-globulin for the management of enterovirus encephalitis. Pediatr Infect Dis J. 1988 May;7(5 Suppl):S30–S33. [PubMed] [Google Scholar]
  105. Efstathiou S., Kemp S., Darby G., Minson A. C. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol. 1989 Apr;70(Pt 4):869–879. doi: 10.1099/0022-1317-70-4-869. [DOI] [PubMed] [Google Scholar]
  106. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Ellis M. N., Keller P. M., Fyfe J. A., Martin J. L., Rooney J. F., Straus S. E., Lehrman S. N., Barry D. W. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother. 1987 Jul;31(7):1117–1125. doi: 10.1128/aac.31.7.1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Elwell L. P., Ferone R., Freeman G. A., Fyfe J. A., Hill J. A., Ray P. H., Richards C. A., Singer S. C., Knick V. B., Rideout J. L. Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U). Antimicrob Agents Chemother. 1987 Feb;31(2):274–280. doi: 10.1128/aac.31.2.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Emanuel D., Cunningham I., Jules-Elysee K., Brochstein J. A., Kernan N. A., Laver J., Stover D., White D. A., Fels A., Polsky B. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988 Nov 15;109(10):777–782. doi: 10.7326/0003-4819-109-10-777. [DOI] [PubMed] [Google Scholar]
  110. Englund J. A., Zimmerman M. E., Swierkosz E. M., Goodman J. L., Scholl D. R., Balfour H. H., Jr Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med. 1990 Mar 15;112(6):416–422. doi: 10.7326/0003-4819-76-3-112-6-416. [DOI] [PubMed] [Google Scholar]
  111. Erice A., Chou S., Biron K. K., Stanat S. C., Balfour H. H., Jr, Jordan M. C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989 Feb 2;320(5):289–293. doi: 10.1056/NEJM198902023200505. [DOI] [PubMed] [Google Scholar]
  112. Erickson J., Neidhart D. J., VanDrie J., Kempf D. J., Wang X. C., Norbeck D. W., Plattner J. J., Rittenhouse J. W., Turon M., Wideburg N. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science. 1990 Aug 3;249(4968):527–533. doi: 10.1126/science.2200122. [DOI] [PubMed] [Google Scholar]
  113. Eriksson B., Helgstrand E., Johansson N. G., Larsson A., Misiorny A., Norén J. O., Philipson L., Stenberg K., Stening G., Stridh S. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother. 1977 Jun;11(6):946–951. doi: 10.1128/aac.11.6.946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Erlich K. S., Jacobson M. A., Koehler J. E., Follansbee S. E., Drennan D. P., Gooze L., Safrin S., Mills J. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann Intern Med. 1989 May 1;110(9):710–713. doi: 10.7326/0003-4819-110-9-710. [DOI] [PubMed] [Google Scholar]
  115. Erlich K. S., Mills J., Chatis P., Mertz G. J., Busch D. F., Follansbee S. E., Grant R. M., Crumpacker C. S. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 2;320(5):293–296. doi: 10.1056/NEJM198902023200506. [DOI] [PubMed] [Google Scholar]
  116. Eron L. J., Judson F., Tucker S., Prawer S., Mills J., Murphy K., Hickey M., Rogers M., Flannigan S., Hien N. Interferon therapy for condylomata acuminata. N Engl J Med. 1986 Oct 23;315(17):1059–1064. doi: 10.1056/NEJM198610233151704. [DOI] [PubMed] [Google Scholar]
  117. Estes J. E., Huang E. S. Stimulation of cellular thymidine kinases by human cytomegalovirus. J Virol. 1977 Oct;24(1):13–21. doi: 10.1128/jvi.24.1.13-21.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Fanning M. M., Read S. E., Benson M., Vas S., Rachlis A., Kozousek V., Mortimer C., Harvey P., Schwartz C., Chew E. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr. 1990;3(5):472–479. [PubMed] [Google Scholar]
  119. Fauci A. S., Schnittman S. M., Poli G., Koenig S., Pantaleo G. NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 Apr 15;114(8):678–693. doi: 10.7326/0003-4819-114-8-678. [DOI] [PubMed] [Google Scholar]
  120. Feldman S., Rodman J., Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis. 1988 Feb;157(2):385–388. doi: 10.1093/infdis/157.2.385. [DOI] [PubMed] [Google Scholar]
  121. Felsenstein D., D'Amico D. J., Hirsch M. S., Neumeyer D. A., Cederberg D. M., de Miranda P., Schooley R. T. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med. 1985 Sep;103(3):377–380. doi: 10.7326/0003-4819-103-3-377. [DOI] [PubMed] [Google Scholar]
  122. Field A. K., Davies M. E., DeWitt C., Perry H. C., Liou R., Germershausen J., Karkas J. D., Ashton W. T., Johnston D. B., Tolman R. L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139–4143. doi: 10.1073/pnas.80.13.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Field H. J., Coen D. M. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol. 1986 Oct;60(1):286–289. doi: 10.1128/jvi.60.1.286-289.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Field H. J., Darby G. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother. 1980 Feb;17(2):209–216. doi: 10.1128/aac.17.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Field H. J. Persistent herpes simplex virus infection and mechanisms of virus drug resistance. Eur J Clin Microbiol Infect Dis. 1989 Aug;8(8):671–680. doi: 10.1007/BF01963751. [DOI] [PubMed] [Google Scholar]
  126. Fischl M. A., Parker C. B., Pettinelli C., Wulfsohn M., Hirsch M. S., Collier A. C., Antoniskis D., Ho M., Richman D. D., Fuchs E. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990 Oct 11;323(15):1009–1014. doi: 10.1056/NEJM199010113231501. [DOI] [PubMed] [Google Scholar]
  127. Fischl M. A., Richman D. D., Causey D. M., Grieco M. H., Bryson Y., Mildvan D., Laskin O. L., Groopman J. E., Volberding P. A., Schooley R. T. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989 Nov 3;262(17):2405–2410. [PubMed] [Google Scholar]
  128. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  129. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  130. Fischl M. A., Uttamchandani R. B., Resnick L., Agarwal R., Fletcher M. A., Patrone-Reese J., Dearmas L., Chidekel J., McCann M., Myers M. A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr. 1991;4(1):1–10. [PubMed] [Google Scholar]
  131. Fisher A. G., Ensoli B., Looney D., Rose A., Gallo R. C., Saag M. S., Shaw G. M., Hahn B. H., Wong-Staal F. Biologically diverse molecular variants within a single HIV-1 isolate. Nature. 1988 Aug 4;334(6181):444–447. doi: 10.1038/334444a0. [DOI] [PubMed] [Google Scholar]
  132. Fox M. P., Otto M. J., McKinlay M. A. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother. 1986 Jul;30(1):110–116. doi: 10.1128/aac.30.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Freitas V. R., Smee D. F., Chernow M., Boehme R., Matthews T. R. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob Agents Chemother. 1985 Aug;28(2):240–245. doi: 10.1128/aac.28.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Friedman-Kien A. E., Eron L. J., Conant M., Growdon W., Badiak H., Bradstreet P. W., Fedorczyk D., Trout J. R., Plasse T. F. Natural interferon alfa for treatment of condylomata acuminata. JAMA. 1988 Jan 22;259(4):533–538. [PubMed] [Google Scholar]
  135. Furman P. A., Barry D. W. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med. 1988 Aug 29;85(2A):176–181. [PubMed] [Google Scholar]
  136. Furman P. A., Coen D. M., St Clair M. H., Schaffer P. A. Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities. J Virol. 1981 Dec;40(3):936–941. doi: 10.1128/jvi.40.3.936-941.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Furman P. A., McGuirt P. V., Keller P. M., Fyfe J. A., Elion G. B. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology. 1980 Apr 30;102(2):420–430. doi: 10.1016/0042-6822(80)90109-9. [DOI] [PubMed] [Google Scholar]
  139. Furman P. A., St Clair M. H., Fyfe J. A., Rideout J. L., Keller P. M., Elion G. B. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol. 1979 Oct;32(1):72–77. doi: 10.1128/jvi.32.1.72-77.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Furman P. A., St Clair M. H., Spector T. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem. 1984 Aug 10;259(15):9575–9579. [PubMed] [Google Scholar]
  141. Fyfe J. A., Keller P. M., Furman P. A., Miller R. L., Elion G. B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978 Dec 25;253(24):8721–8727. [PubMed] [Google Scholar]
  142. Gadler H., Larsson A., Sølver E. Nucleic acid hybridization, a method to determine effects of antiviral compounds on herpes simplex virus type 1 DNA synthesis. Antiviral Res. 1984 Apr;4(1-2):63–70. doi: 10.1016/0166-3542(84)90026-3. [DOI] [PubMed] [Google Scholar]
  143. Galbraith A. W., Oxford J. S., Schild G. C., Watson G. I. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet. 1969 Nov 15;2(7629):1026–1028. doi: 10.1016/s0140-6736(69)90639-4. [DOI] [PubMed] [Google Scholar]
  144. Gateley A., Gander R. M., Johnson P. C., Kit S., Otsuka H., Kohl S. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis. 1990 Apr;161(4):711–715. doi: 10.1093/infdis/161.4.711. [DOI] [PubMed] [Google Scholar]
  145. Gelmon K., Montaner J. S., Fanning M., Smith J. R., Falutz J., Tsoukas C., Gill J., Wells G., O'Shaughnessy M., Wainberg M. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS. 1989 Sep;3(9):555–561. doi: 10.1097/00002030-198909000-00001. [DOI] [PubMed] [Google Scholar]
  146. Gershon A. A., Steinberg S., Brunell P. A. Zoster immune globulin. A further assessment. N Engl J Med. 1974 Jan 31;290(5):243–245. doi: 10.1056/NEJM197401312900503. [DOI] [PubMed] [Google Scholar]
  147. Gilbert B. E., Wilson S. Z., Knight V., Couch R. B., Quarles J. M., Dure L., Hayes N., Willis G. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 1985 Mar;27(3):309–313. doi: 10.1128/aac.27.3.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Gilquin J., Weiss L., Kazatchkine M. D. Genital and oral erosions induced by foscarnet. Lancet. 1990 Feb 3;335(8684):287–287. doi: 10.1016/0140-6736(90)90101-a. [DOI] [PubMed] [Google Scholar]
  149. Goodrich J. M., Mori M., Gleaves C. A., Du Mond C., Cays M., Ebeling D. F., Buhles W. C., DeArmond B., Meyers J. D. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991 Dec 5;325(23):1601–1607. doi: 10.1056/NEJM199112053252303. [DOI] [PubMed] [Google Scholar]
  150. Goswami B. B., Borek E., Sharma O. K., Fujitaki J., Smith R. A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun. 1979 Aug 13;89(3):830–836. doi: 10.1016/0006-291x(79)91853-9. [DOI] [PubMed] [Google Scholar]
  151. Gottlieb M. S., Zackin R. A., Fiala M., Henry D. H., Marcel A. J., Combs K. L., Vieira J., Liebman H. A., Cone L. A., Hillman K. S. Response to treatment with the leukocyte-derived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex. A multicenter, double-blind, placebo-controlled trial. Ann Intern Med. 1991 Jul 15;115(2):84–91. doi: 10.7326/0003-4819-115-2-84. [DOI] [PubMed] [Google Scholar]
  152. Greffe B. S., Dooley S. L., Deddish R. B., Krasny H. C. Transplacental passage of acyclovir. J Pediatr. 1986 Jun;108(6):1020–1021. doi: 10.1016/s0022-3476(86)80954-4. [DOI] [PubMed] [Google Scholar]
  153. Groopman J. E., Mitsuyasu R. T., DeLeo M. J., Oette D. H., Golde D. W. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med. 1987 Sep 3;317(10):593–598. doi: 10.1056/NEJM198709033171003. [DOI] [PubMed] [Google Scholar]
  154. Grundy J. E., Shanley J. D., Griffiths P. D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet. 1987 Oct 31;2(8566):996–999. doi: 10.1016/s0140-6736(87)92560-8. [DOI] [PubMed] [Google Scholar]
  155. Haake D. A., Zakowski P. C., Haake D. L., Bryson Y. J. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis. 1990 Sep-Oct;12(5):788–798. doi: 10.1093/clinids/12.5.788. [DOI] [PubMed] [Google Scholar]
  156. Hadler S. C., Erben J. J., Matthews D., Starko K., Francis D. P., Maynard J. E. Effect of immunoglobulin on hepatitis A in day-care centers. JAMA. 1983 Jan 7;249(1):48–53. [PubMed] [Google Scholar]
  157. Hall C. B., Dolin R., Gala C. L., Markovitz D. M., Zhang Y. Q., Madore P. H., Disney F. A., Talpey W. B., Green J. L., Francis A. B. Children with influenza A infection: treatment with rimantadine. Pediatrics. 1987 Aug;80(2):275–282. [PubMed] [Google Scholar]
  158. Hall C. B., McBride J. T., Gala C. L., Hildreth S. W., Schnabel K. C. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA. 1985 Dec 6;254(21):3047–3051. [PubMed] [Google Scholar]
  159. Hall C. B., McBride J. T., Walsh E. E., Bell D. M., Gala C. L., Hildreth S., Ten Eyck L. G., Hall W. J. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983 Jun 16;308(24):1443–1447. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
  160. Harbison M. A., De Girolami P. C., Jenkins R. L., Hammer S. M. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation. 1988 Jul;46(1):82–88. doi: 10.1097/00007890-198807000-00015. [DOI] [PubMed] [Google Scholar]
  161. Hardy W. D. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr. 1991;4 (Suppl 1):S22–S28. [PubMed] [Google Scholar]
  162. Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
  163. Hartshorn K. L., Vogt M. W., Chou T. C., Blumberg R. S., Byington R., Schooley R. T., Hirsch M. S. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother. 1987 Feb;31(2):168–172. doi: 10.1128/aac.31.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Hay A. J., Wolstenholme A. J., Skehel J. J., Smith M. H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985 Nov;4(11):3021–3024. doi: 10.1002/j.1460-2075.1985.tb04038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Hay A. J., Zambon M. C., Wolstenholme A. J., Skehel J. J., Smith M. H. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother. 1986 Oct;18 (Suppl B):19–29. doi: 10.1093/jac/18.supplement_b.19. [DOI] [PubMed] [Google Scholar]
  166. Hayden F. G., Albrecht J. K., Kaiser D. L., Gwaltney J. M., Jr Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med. 1986 Jan 9;314(2):71–75. doi: 10.1056/NEJM198601093140202. [DOI] [PubMed] [Google Scholar]
  167. Hayden F. G., Belshe R. B., Clover R. D., Hay A. J., Oakes M. G., Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989 Dec 21;321(25):1696–1702. doi: 10.1056/NEJM198912213212502. [DOI] [PubMed] [Google Scholar]
  168. Hayden F. G., Cote K. M., Douglas R. G., Jr Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother. 1980 May;17(5):865–870. doi: 10.1128/aac.17.5.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. Hayden F. G., Kaiser D. L., Albrecht J. K. Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother. 1988 Feb;32(2):224–230. doi: 10.1128/aac.32.2.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Hayden F. G., Monto A. S. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother. 1986 Feb;29(2):339–341. doi: 10.1128/aac.29.2.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Heagy W., Crumpacker C., Lopez P. A., Finberg R. W. Inhibition of immune functions by antiviral drugs. J Clin Invest. 1991 Jun;87(6):1916–1924. doi: 10.1172/JCI115217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Hecht D. W., Snydman D. R., Crumpacker C. S., Werner B. G., Heinze-Lacey B. Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia. J Infect Dis. 1988 Jan;157(1):187–190. doi: 10.1093/infdis/157.1.187. [DOI] [PubMed] [Google Scholar]
  173. Heinemann M. H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol. 1989 Dec;107(12):1767–1772. doi: 10.1001/archopht.1989.01070020849025. [DOI] [PubMed] [Google Scholar]
  174. Helgstrand E., Eriksson B., Johansson N. G., Lannerö B., Larsson A., Misiorny A., Norén J. O., Sjöberg B., Stenberg K., Stening G. Trisodium phosphonoformate, a new antiviral compound. Science. 1978 Sep 1;201(4358):819–821. doi: 10.1126/science.210500. [DOI] [PubMed] [Google Scholar]
  175. Henderly D. E., Freeman W. R., Causey D. M., Rao N. A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 1987 Apr;94(4):425–434. doi: 10.1016/s0161-6420(87)33454-2. [DOI] [PubMed] [Google Scholar]
  176. Henry K., Cantrill H., Fletcher C., Chinnock B. J., Balfour H. H., Jr Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 1987 Jan 15;103(1):17–23. doi: 10.1016/s0002-9394(14)74163-7. [DOI] [PubMed] [Google Scholar]
  177. Henry K., Chinnock B. J., Quinn R. P., Fletcher C. V., de Miranda P., Balfour H. H., Jr Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA. 1988 May 27;259(20):3023–3026. [PubMed] [Google Scholar]
  178. Hersh E. M., Brewton G., Abrams D., Bartlett J., Galpin J., Gill P., Gorter R., Gottlieb M., Jonikas J. J., Landesman S. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538–1544. [PubMed] [Google Scholar]
  179. Hill J. M., Sedarati F., Javier R. T., Wagner E. K., Stevens J. G. Herpes simplex virus latent phase transcription facilitates in vivo reactivation. Virology. 1990 Jan;174(1):117–125. doi: 10.1016/0042-6822(90)90060-5. [DOI] [PubMed] [Google Scholar]
  180. Hirsch M. S. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J Infect Dis. 1990 May;161(5):845–857. doi: 10.1093/infdis/161.5.845. [DOI] [PubMed] [Google Scholar]
  181. Hirsch M. S., Schooley R. T., Cosimi A. B., Russell P. S., Delmonico F. L., Tolkoff-Rubin N. E., Herrin J. T., Cantell K., Farrell M. L., Rota T. R. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med. 1983 Jun 23;308(25):1489–1493. doi: 10.1056/NEJM198306233082501. [DOI] [PubMed] [Google Scholar]
  182. Ho D. D., Hartshorn K. L., Rota T. R., Andrews C. A., Kaplan J. C., Schooley R. T., Hirsch M. S. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet. 1985 Mar 16;1(8429):602–604. doi: 10.1016/s0140-6736(85)92144-0. [DOI] [PubMed] [Google Scholar]
  183. Ho H. T., Hitchcock M. J. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother. 1989 Jun;33(6):844–849. doi: 10.1128/aac.33.6.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Hochster H., Dieterich D., Bozzette S., Reichman R. C., Connor J. D., Liebes L., Sonke R. L., Spector S. A., Valentine F., Pettinelli C. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med. 1990 Jul 15;113(2):111–117. doi: 10.7326/0003-4819-113-2-111. [DOI] [PubMed] [Google Scholar]
  185. Hodge R. A., Perkins R. M. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother. 1989 Feb;33(2):223–229. doi: 10.1128/aac.33.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Hoffmann C. E., Neumayer E. M., Haff R. F., Goldsby R. A. Mode of Action of the Antiviral Activity of Amantadine in Tissue Culture. J Bacteriol. 1965 Sep;90(3):623–628. doi: 10.1128/jb.90.3.623-628.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Holland G. N., Sakamoto M. J., Hardy D., Sidikaro Y., Kreiger A. E., Frenkel L. M. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Arch Ophthalmol. 1986 Dec;104(12):1794–1800. doi: 10.1001/archopht.1986.01050240068042. [DOI] [PubMed] [Google Scholar]
  188. Hoofnagle J. H., Peters M., Mullen K. D., Jones D. B., Rustgi V., Di Bisceglie A., Hallahan C., Park Y., Meschievitz C., Jones E. A. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 1988 Nov;95(5):1318–1325. doi: 10.1016/0016-5085(88)90367-8. [DOI] [PubMed] [Google Scholar]
  189. Howell C. L., Miller M. J. Rapid method for determining the susceptibility of herpes simplex virus to acyclovir. Diagn Microbiol Infect Dis. 1984 Apr;2(2):77–84. doi: 10.1016/0732-8893(84)90001-4. [DOI] [PubMed] [Google Scholar]
  190. Hruska J. F., Bernstein J. M., Douglas R. G., Jr, Hall C. B. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother. 1980 May;17(5):770–775. doi: 10.1128/aac.17.5.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  191. Huff J. C., Bean B., Balfour H. H., Jr, Laskin O. L., Connor J. D., Corey L., Bryson Y. J., McGuirt P. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988 Aug 29;85(2A):84–89. [PubMed] [Google Scholar]
  192. Indulen M. K., Feldblum R. L. Obtaining of a virazole-resistant fowl plague virus mutant. Acta Virol. 1982 Jan;26(1-2):109–109. [PubMed] [Google Scholar]
  193. Jabs D. A., Enger C., Bartlett J. G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989 Jan;107(1):75–80. doi: 10.1001/archopht.1989.01070010077031. [DOI] [PubMed] [Google Scholar]
  194. Jackson G. G., Paul D. A., Falk L. A., Rubenis M., Despotes J. C., Mack D., Knigge M., Emeson E. E. Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). Ann Intern Med. 1988 Feb;108(2):175–180. doi: 10.7326/0003-4819-108-2-175. [DOI] [PubMed] [Google Scholar]
  195. Jackson G. G., Perkins J. T., Rubenis M., Paul D. A., Knigge M., Despotes J. C., Spencer P. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988 Sep 17;2(8612):647–652. doi: 10.1016/s0140-6736(88)90468-0. [DOI] [PubMed] [Google Scholar]
  196. Jacobsen M. A., van der Horst C., Causey D. M., Dehlinger M., Hafner R., Mills J. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053). J Infect Dis. 1991 Jun;163(6):1219–1222. doi: 10.1093/infdis/163.6.1219. [DOI] [PubMed] [Google Scholar]
  197. Jacobson M. A., Berger T. G., Fikrig S., Becherer P., Moohr J. W., Stanat S. C., Biron K. K. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990 Feb 1;112(3):187–191. doi: 10.7326/0003-4819-112-3-187. [DOI] [PubMed] [Google Scholar]
  198. Jacobson M. A., Crowe S., Levy J., Aweeka F., Gambertoglio J., McManus N., Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct;158(4):862–865. [PubMed] [Google Scholar]
  199. Jacobson M. A., O'Donnell J. J., Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1989 May;33(5):736–741. doi: 10.1128/aac.33.5.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  200. Jacobson M. A., de Miranda P., Cederberg D. M., Burnette T., Cobb E., Brodie H. R., Mills J. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother. 1987 Aug;31(8):1251–1254. doi: 10.1128/aac.31.8.1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  201. Japour A. J., Chatis P. A., Eigenrauch H. A., Crumpacker C. S. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3092–3096. doi: 10.1073/pnas.88.8.3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Johnson M. A., Ahluwalia G., Connelly M. C., Cooney D. A., Broder S., Johns D. G., Fridland A. Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem. 1988 Oct 25;263(30):15354–15357. [PubMed] [Google Scholar]
  203. KAUFMAN H., MARTOLA E. L., DOHLMAN C. Use of 5-iodo-2'-deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch Ophthalmol. 1962 Aug;68:235–239. doi: 10.1001/archopht.1962.00960030239015. [DOI] [PubMed] [Google Scholar]
  204. Kahn J. O., Allan J. D., Hodges T. L., Kaplan L. D., Arri C. J., Fitch H. F., Izu A. E., Mordenti J., Sherwin J. E., Groopman J. E. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med. 1990 Feb 15;112(4):254–261. doi: 10.7326/0003-4819-112-4-. [DOI] [PubMed] [Google Scholar]
  205. Kaplowitz L. G., Baker D., Gelb L., Blythe J., Hale R., Frost P., Crumpacker C., Rabinovich S., Peacock J. E., Jr, Herndon J. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group. JAMA. 1991 Feb 13;265(6):747–751. [PubMed] [Google Scholar]
  206. Karpas A., Fleet G. W., Dwek R. A., Petursson S., Namgoong S. K., Ramsden N. G., Jacob G. S., Rademacher T. W. Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9229–9233. doi: 10.1073/pnas.85.23.9229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  207. Kato N., Eggers H. J. Inhibition of uncoating of fowl plague virus by l-adamantanamine hydrochloride. Virology. 1969 Apr;37(4):632–641. doi: 10.1016/0042-6822(69)90281-5. [DOI] [PubMed] [Google Scholar]
  208. Keith B. R., White G., Wilson H. R. In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections. Antimicrob Agents Chemother. 1989 Apr;33(4):479–483. doi: 10.1128/aac.33.4.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  209. Keller P. M., Fyfe J. A., Beauchamp L., Lubbers C. M., Furman P. A., Schaeffer H. J., Elion G. B. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol. 1981 Nov 15;30(22):3071–3077. doi: 10.1016/0006-2952(81)90495-0. [DOI] [PubMed] [Google Scholar]
  210. Kende M., Alving C. R., Rill W. L., Swartz G. M., Jr, Canonico P. G. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother. 1985 Jun;27(6):903–907. doi: 10.1128/aac.27.6.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  211. Kim S., Scheerer S., Geyer M. A., Howell S. B. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J Infect Dis. 1990 Sep;162(3):750–752. doi: 10.1093/infdis/162.3.750. [DOI] [PubMed] [Google Scholar]
  212. Klintmalm G., Lönnqvist B., Oberg B., Gahrton G., Lernestedt J. O., Lundgren G., Ringdén O., Robert K. H., Wahren B., Groth C. G. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis. 1985;17(2):157–163. doi: 10.3109/inf.1985.17.issue-2.06. [DOI] [PubMed] [Google Scholar]
  213. Knight V., McClung H. W., Wilson S. Z., Waters B. K., Quarles J. M., Cameron R. W., Greggs S. E., Zerwas J. M., Couch R. B. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981 Oct 31;2(8253):945–949. doi: 10.1016/s0140-6736(81)91152-1. [DOI] [PubMed] [Google Scholar]
  214. Knox K. K., Drobyski W. R., Carrigan D. R. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet. 1991 May 25;337(8752):1292–1293. doi: 10.1016/0140-6736(91)92965-5. [DOI] [PubMed] [Google Scholar]
  215. Kochhar D. M., Penner J. D., Knudsen T. B. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol. 1980 Jan;52(1):99–112. doi: 10.1016/0041-008x(80)90252-5. [DOI] [PubMed] [Google Scholar]
  216. Koff W. C., Fidler I. J., Showalter S. D., Chakrabarty M. K., Hampar B., Ceccorulli L. M., Kleinerman E. S. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science. 1984 Jun 1;224(4652):1007–1009. doi: 10.1126/science.6426057. [DOI] [PubMed] [Google Scholar]
  217. Konopka K., Davis B. R., Larsen C. E., Alford D. R., Debs R. J., Düzgüneş N. Liposomes modulate human immunodeficiency virus infectivity. J Gen Virol. 1990 Dec;71(Pt 12):2899–2907. doi: 10.1099/0022-1317-71-12-2899. [DOI] [PubMed] [Google Scholar]
  218. Korenman J., Baker B., Waggoner J., Everhart J. E., Di Bisceglie A. M., Hoofnagle J. H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med. 1991 Apr 15;114(8):629–634. doi: 10.7326/0003-4819-114-8-629. [DOI] [PubMed] [Google Scholar]
  219. Kornbluth R. S., Oh P. S., Munis J. R., Cleveland P. H., Richman D. D. The role of interferons in the control of HIV replication in macrophages. Clin Immunol Immunopathol. 1990 Feb;54(2):200–219. doi: 10.1016/0090-1229(90)90082-2. [DOI] [PubMed] [Google Scholar]
  220. Kornhauser D. M., Petty B. G., Hendrix C. W., Woods A. S., Nerhood L. J., Bartlett J. G., Lietman P. S. Probenecid and zidovudine metabolism. Lancet. 1989 Aug 26;2(8661):473–475. doi: 10.1016/s0140-6736(89)92087-4. [DOI] [PubMed] [Google Scholar]
  221. Kotler M., Katz R. A., Danho W., Leis J., Skalka A. M. Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4185–4189. doi: 10.1073/pnas.85.12.4185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  222. Koup R. A., Merluzzi V. J., Hargrave K. D., Adams J., Grozinger K., Eckner R. J., Sullivan J. L. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis. 1991 May;163(5):966–970. doi: 10.1093/infdis/163.5.966. [DOI] [PubMed] [Google Scholar]
  223. Kovacs J. A., Deyton L., Davey R., Falloon J., Zunich K., Lee D., Metcalf J. A., Bigley J. W., Sawyer L. A., Zoon K. C. Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1989 Aug 15;111(4):280–287. doi: 10.7326/0003-4819-111-4-280. [DOI] [PubMed] [Google Scholar]
  224. Koyanagi Y., O'Brien W. A., Zhao J. Q., Golde D. W., Gasson J. C., Chen I. S. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science. 1988 Sep 23;241(4873):1673–1675. doi: 10.1126/science.241.4873.1673. [DOI] [PubMed] [Google Scholar]
  225. Krieger J. N., Coombs R. W., Collier A. C., Ross S. O., Chaloupka K., Cummings D. K., Murphy V. L., Corey L. Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis. 1991 Feb;163(2):386–388. doi: 10.1093/infdis/163.2.386. [DOI] [PubMed] [Google Scholar]
  226. Krigel R. L. Reversible neurotoxicity due to oral acyclovir in a patient with chronic lymphocytic leukemia. J Infect Dis. 1986 Jul;154(1):189–189. doi: 10.1093/infdis/154.1.189. [DOI] [PubMed] [Google Scholar]
  227. Krown S. E., Gold J. W., Niedzwiecki D., Bundow D., Flomenberg N., Gansbacher B., Brew B. J. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1990 Jun 1;112(11):812–821. doi: 10.7326/0003-4819-112-11-812. [DOI] [PubMed] [Google Scholar]
  228. Kuhls T. L., Sacher J., Pineda E., Santomauro D., Wiesmeier E., Growdon W. A., Bryson Y. J. Suppression of recurrent genital herpes simplex virus infection with recombinant alpha 2 interferon. J Infect Dis. 1986 Sep;154(3):437–442. doi: 10.1093/infdis/154.3.437. [DOI] [PubMed] [Google Scholar]
  229. Lambert J. S., Seidlin M., Reichman R. C., Plank C. S., Laverty M., Morse G. D., Knupp C., McLaren C., Pettinelli C., Valentine F. T. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333–1340. doi: 10.1056/NEJM199005103221901. [DOI] [PubMed] [Google Scholar]
  230. Land S., Terloar G., McPhee D., Birch C., Doherty R., Cooper D., Gust I. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis. 1990 Feb;161(2):326–329. doi: 10.1093/infdis/161.2.326. [DOI] [PubMed] [Google Scholar]
  231. Lane H. C., Davey V., Kovacs J. A., Feinberg J., Metcalf J. A., Herpin B., Walker R., Deyton L., Davey R. T., Jr, Falloon J. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med. 1990 Jun 1;112(11):805–811. doi: 10.7326/0003-4819-112-11-805. [DOI] [PubMed] [Google Scholar]
  232. Lane H. C., Kovacs J. A., Feinberg J., Herpin B., Davey V., Walker R., Deyton L., Metcalf J. A., Baseler M., Salzman N. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1218–1222. doi: 10.1016/s0140-6736(88)90811-2. [DOI] [PubMed] [Google Scholar]
  233. Lane H. C., Masur H., Edgar L. C., Whalen G., Rook A. H., Fauci A. S. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983 Aug 25;309(8):453–458. doi: 10.1056/NEJM198308253090803. [DOI] [PubMed] [Google Scholar]
  234. Lane H. C., Zunich K. M., Wilson W., Cefali F., Easter M., Kovacs J. A., Masur H., Leitman S. F., Klein H. G., Steis R. G. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1990 Oct 1;113(7):512–519. doi: 10.7326/0003-4819-113-7-512. [DOI] [PubMed] [Google Scholar]
  235. Lange J. M., Boucher C. A., Hollak C. E., Wiltink E. H., Reiss P., van Royen E. A., Roos M., Danner S. A., Goudsmit J. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med. 1990 May 10;322(19):1375–1377. doi: 10.1056/NEJM199005103221907. [DOI] [PubMed] [Google Scholar]
  236. Larder B. A., Chesebro B., Richman D. D. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother. 1990 Mar;34(3):436–441. doi: 10.1128/aac.34.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  237. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  238. Larder B. A., Darby G. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities. Virology. 1985 Oct 30;146(2):262–271. doi: 10.1016/0042-6822(85)90009-1. [DOI] [PubMed] [Google Scholar]
  239. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  240. Larder B. A., Purifoy D. J., Powell K. L., Bradley C., Kemp S., Tisdale M., Ertl P., Darby G. K., Stammers D. Structural studies of the acquired immunodeficiency syndrome virus reverse transcriptase. Am J Med. 1988 Aug 29;85(2A):173–175. [PubMed] [Google Scholar]
  241. Larsson A., Stenberg K., Oberg B. Reversible inhibition of cellular metabolism by ribavirin. Antimicrob Agents Chemother. 1978 Feb;13(2):154–158. doi: 10.1128/aac.13.2.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  242. Laskin O. L., Cederberg D. M., Mills J., Eron L. J., Mildvan D., Spector S. A. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med. 1987 Aug;83(2):201–207. doi: 10.1016/0002-9343(87)90685-1. [DOI] [PubMed] [Google Scholar]
  243. Lau A. S., Hannigan G. E., Freedman M. H., Williams B. R. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest. 1986 May;77(5):1632–1638. doi: 10.1172/JCI112480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  244. Laurence J. Molecular interactions among herpesviruses and human immunodeficiency viruses. J Infect Dis. 1990 Aug;162(2):338–346. doi: 10.1093/infdis/162.2.338. [DOI] [PubMed] [Google Scholar]
  245. Lehoang P., Girard B., Robinet M., Marcel P., Zazoun L., Matheron S., Rozenbaum W., Katlama C., Morer I., Lernestedt J. O. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1989 Jun;96(6):865–874. doi: 10.1016/s0161-6420(89)32824-7. [DOI] [PubMed] [Google Scholar]
  246. Lehrman S. N., Douglas J. M., Corey L., Barry D. W. Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med. 1986 Jun;104(6):786–790. doi: 10.7326/0003-4819-104-6-786. [DOI] [PubMed] [Google Scholar]
  247. Leinbach S. S., Reno J. M., Lee L. F., Isbell A. F., Boezi J. A. Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase. Biochemistry. 1976 Jan 27;15(2):426–430. doi: 10.1021/bi00647a029. [DOI] [PubMed] [Google Scholar]
  248. Lin J. C., Smith M. C., Pagano J. S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol. 1984 Apr;50(1):50–55. doi: 10.1128/jvi.50.1.50-55.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  249. Lin J. C., Zhang Z. X., Smith M. C., Biron K., Pagano J. S. Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus. Antimicrob Agents Chemother. 1988 Feb;32(2):265–267. doi: 10.1128/aac.32.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  250. Little J. W., Hall W. J., Douglas R. G., Jr, Hyde R. W., Speers D. M. Amantadine effect on peripheral airways abnormalities in influenza. A study in 15 students with natural influenza A infection. Ann Intern Med. 1976 Aug;85(2):177–182. doi: 10.7326/0003-4819-85-2-177. [DOI] [PubMed] [Google Scholar]
  251. Lok A. S., Lai C. L., Wu P. C., Leung E. K. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet. 1988 Aug 6;2(8606):298–302. doi: 10.1016/s0140-6736(88)92355-0. [DOI] [PubMed] [Google Scholar]
  252. Lubeck M. D., Schulman J. L., Palese P. Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein. J Virol. 1978 Dec;28(3):710–716. doi: 10.1128/jvi.28.3.710-716.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  253. Luby J. P., Gnann J. W., Jr, Alexander W. J., Hatcher V. A., Friedman-Kien A. E., Klein R. J., Keyserling H., Nahmias A., Mills J., Schachter J. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J Infect Dis. 1984 Jul;150(1):1–6. doi: 10.1093/infdis/150.1.1. [DOI] [PubMed] [Google Scholar]
  254. Machida H., Kuninaka A., Yoshino H. Inhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virus. Antimicrob Agents Chemother. 1982 Feb;21(2):358–361. doi: 10.1128/aac.21.2.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  255. Mansuri M. M., Starrett J. E., Jr, Ghazzouli I., Hitchcock M. J., Sterzycki R. Z., Brankovan V., Lin T. S., August E. M., Prusoff W. H., Sommadossi J. P. 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J Med Chem. 1989 Feb;32(2):461–466. doi: 10.1021/jm00122a029. [DOI] [PubMed] [Google Scholar]
  256. Mar E. C., Cheng Y. C., Huang E. S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983 Oct;24(4):518–521. doi: 10.1128/aac.24.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  257. Mar E. C., Chiou J. F., Cheng Y. C., Huang E. S. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Virol. 1985 Mar;53(3):776–780. doi: 10.1128/jvi.53.3.776-780.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  258. Marker S. C., Howard R. J., Groth K. E., Mastri A. R., Simmons R. L., Balfour H. H., Jr A trial of vidarabine for cytomegalovirus infection in renal transplant patients. Arch Intern Med. 1980 Nov;140(11):1441–1444. [PubMed] [Google Scholar]
  259. Marks G. L., Nolan P. E., Erlich K. S., Ellis M. N. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS. Rev Infect Dis. 1989 May-Jun;11(3):474–476. doi: 10.1093/clinids/11.3.474. [DOI] [PubMed] [Google Scholar]
  260. Matsukura M., Zon G., Shinozuka K., Robert-Guroff M., Shimada T., Stein C. A., Mitsuya H., Wong-Staal F., Cohen J. S., Broder S. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244–4248. doi: 10.1073/pnas.86.11.4244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  261. McCammon J. A. Computer-aided molecular design. Science. 1987 Oct 23;238(4826):486–491. doi: 10.1126/science.3310236. [DOI] [PubMed] [Google Scholar]
  262. McClung H. W., Knight V., Gilbert B. E., Wilson S. Z., Quarles J. M., Divine G. W. Ribavirin aerosol treatment of influenza B virus infection. JAMA. 1983 May 20;249(19):2671–2674. [PubMed] [Google Scholar]
  263. McCormick J. B., Getchell J. P., Mitchell S. W., Hicks D. R. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet. 1984 Dec 15;2(8416):1367–1369. doi: 10.1016/s0140-6736(84)92060-9. [DOI] [PubMed] [Google Scholar]
  264. McCormick J. B., King I. J., Webb P. A., Scribner C. L., Craven R. B., Johnson K. M., Elliott L. H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986 Jan 2;314(1):20–26. doi: 10.1056/NEJM198601023140104. [DOI] [PubMed] [Google Scholar]
  265. McKeating J. A., Griffiths P. D., Weiss R. A. HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor. Nature. 1990 Feb 15;343(6259):659–661. doi: 10.1038/343659a0. [DOI] [PubMed] [Google Scholar]
  266. McKendrick M. W., McGill J. I., White J. E., Wood M. J. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed) 1986 Dec 13;293(6561):1529–1532. doi: 10.1136/bmj.293.6561.1529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  267. McKinney R. E., Jr, Katz S. L., Wilfert C. M. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis. 1987 Mar-Apr;9(2):334–356. doi: 10.1093/clinids/9.2.334. [DOI] [PubMed] [Google Scholar]
  268. McKinney R. E., Jr, Maha M. A., Connor E. M., Feinberg J., Scott G. B., Wulfsohn M., McIntosh K., Borkowsky W., Modlin J. F., Weintrub P. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med. 1991 Apr 11;324(15):1018–1025. doi: 10.1056/NEJM199104113241503. [DOI] [PubMed] [Google Scholar]
  269. McLaren C., Ellis M. N., Hunter G. A. A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. Antiviral Res. 1983 Nov;3(4):223–234. doi: 10.1016/0166-3542(83)90001-3. [DOI] [PubMed] [Google Scholar]
  270. Melder R. J., Balachandran R., Rinaldo C. R., Gupta P., Whiteside T. L., Herberman R. B. Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells. AIDS Res Hum Retroviruses. 1990 Aug;6(8):1011–1015. doi: 10.1089/aid.1990.6.1011. [DOI] [PubMed] [Google Scholar]
  271. Merigan T. C., Rand K. H., Pollard R. B., Abdallah P. S., Jordan G. W., Fried R. P. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med. 1978 May 4;298(18):981–987. doi: 10.1056/NEJM197805042981801. [DOI] [PubMed] [Google Scholar]
  272. Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  273. Merigan T. C., Skowron G., Bozzette S. A., Richman D., Uttamchandani R., Fischl M., Schooley R., Hirsch M., Soo W., Pettinelli C. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med. 1989 Feb 1;110(3):189–194. doi: 10.7326/0003-4819-110-3-189. [DOI] [PubMed] [Google Scholar]
  274. Merluzzi V. J., Hargrave K. D., Labadia M., Grozinger K., Skoog M., Wu J. C., Shih C. K., Eckner K., Hattox S., Adams J. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411–1413. doi: 10.1126/science.1701568. [DOI] [PubMed] [Google Scholar]
  275. Mertz G. J., Jones C. C., Mills J., Fife K. H., Lemon S. M., Stapleton J. T., Hill E. L., Davis L. G. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA. 1988 Jul 8;260(2):201–206. [PubMed] [Google Scholar]
  276. Meyers J. D., Flournoy N., Sanders J. E., McGuffin R. W., Newton B. A., Fisher L. D., Lum L. G., Appelbaum F. R., Doney K., Sullivan K. M. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med. 1987 Dec;107(6):809–816. doi: 10.7326/0003-4819-107-6-809. [DOI] [PubMed] [Google Scholar]
  277. Meyers J. D., Leszczynski J., Zaia J. A., Flournoy N., Newton B., Snydman D. R., Wright G. G., Levin M. J., Thomas E. D. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med. 1983 Apr;98(4):442–446. doi: 10.7326/0003-4819-98-4-442. [DOI] [PubMed] [Google Scholar]
  278. Meyers J. D., Reed E. C., Shepp D. H., Thornquist M., Dandliker P. S., Vicary C. A., Flournoy N., Kirk L. E., Kersey J. H., Thomas E. D. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988 Jan 14;318(2):70–75. doi: 10.1056/NEJM198801143180202. [DOI] [PubMed] [Google Scholar]
  279. Meyers J. D., Wade J. C., Mitchell C. D., Saral R., Lietman P. S., Durack D. T., Levin M. J., Segreti A. C., Balfour H. H., Jr Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med. 1982 Jul 20;73(1A):229–235. doi: 10.1016/0002-9343(82)90097-3. [DOI] [PubMed] [Google Scholar]
  280. Miles S. A., Mitsuyasu R. T., Moreno J., Baldwin G., Alton N. K., Souza L., Glaspy J. A. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood. 1991 May 15;77(10):2109–2117. [PubMed] [Google Scholar]
  281. Miller W. H., Miller R. L. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem. 1980 Aug 10;255(15):7204–7207. [PubMed] [Google Scholar]
  282. Mindel A., Adler M. W., Sutherland S., Fiddian A. P. Intravenous acyclovir treatment for primary genital herpes. Lancet. 1982 Mar 27;1(8274):697–700. doi: 10.1016/s0140-6736(82)92618-6. [DOI] [PubMed] [Google Scholar]
  283. Mindel A., Weller I. V., Faherty A., Sutherland S., Hindley D., Fiddian A. P., Adler M. W. Prophylactic oral acyclovir in recurrent genital herpes. Lancet. 1984 Jul 14;2(8394):57–59. doi: 10.1016/s0140-6736(84)90237-x. [DOI] [PubMed] [Google Scholar]
  284. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  285. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  286. Monto A. S., Gunn R. A., Bandyk M. G., King C. L. Prevention of Russian influenza by amantadine. JAMA. 1979 Mar 9;241(10):1003–1007. [PubMed] [Google Scholar]
  287. Moore R. D., Kessler H., Richman D. D., Flexner C., Chaisson R. E. Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. JAMA. 1991 May 1;265(17):2208–2211. [PubMed] [Google Scholar]
  288. Nemunaitis J., Rabinowe S. N., Singer J. W., Bierman P. J., Vose J. M., Freedman A. S., Onetto N., Gillis S., Oette D., Gold M. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991 Jun 20;324(25):1773–1778. doi: 10.1056/NEJM199106203242504. [DOI] [PubMed] [Google Scholar]
  289. Nilsen A. E., Aasen T., Halsos A. M., Kinge B. R., Tjøtta E. A., Wikström K., Fiddian A. P. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982 Sep 11;2(8298):571–573. doi: 10.1016/s0140-6736(82)90658-4. [DOI] [PubMed] [Google Scholar]
  290. Norley S. G., Huang L., Rouse B. T. Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cells: an effective means of inhibiting virus replication in vitro. J Immunol. 1986 Jan;136(2):681–685. [PubMed] [Google Scholar]
  291. Nyerges G., Meszner Z., Gyarmati E., Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis. 1988 Feb;157(2):309–313. doi: 10.1093/infdis/157.2.309. [DOI] [PubMed] [Google Scholar]
  292. O'Brien J. J., Campoli-Richards D. M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar;37(3):233–309. doi: 10.2165/00003495-198937030-00002. [DOI] [PubMed] [Google Scholar]
  293. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther. 1989;40(2):213–285. doi: 10.1016/0163-7258(89)90097-1. [DOI] [PubMed] [Google Scholar]
  294. Ogle J. W., Toltzis P., Parker W. D., Alvarez N., McIntosh K., Levin M. J., Lauer B. A. Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis. 1989 Apr;159(4):748–750. doi: 10.1093/infdis/159.4.748. [DOI] [PubMed] [Google Scholar]
  295. Oker-Blom N., Hovi T., Leinikki P., Palosuo T., Pettersson R., Suni J. Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: a controlled field trial. Br Med J. 1970 Sep 19;3(5724):676–678. doi: 10.1136/bmj.3.5724.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  296. Oksenhendler E., Bierling P., Ferchal F., Clauvel J. P., Seligmann M. Zidovudine for thrombocytopenic purpura related to human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989 Mar 1;110(5):365–368. doi: 10.7326/0003-4819-110-5-365. [DOI] [PubMed] [Google Scholar]
  297. Oleson D., Grierson H., Goldsmith J., Purtilo D. T., Johnson D. Augmentation of natural cytotoxicity by leucine enkephalin in cultured peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Clin Immunol Immunopathol. 1989 Jun;51(3):386–395. doi: 10.1016/0090-1229(89)90036-6. [DOI] [PubMed] [Google Scholar]
  298. PRUSOFF W. H. A REVIEW OF SOME ASPECTS OF 5-IODODEOXYURIDINE AND AZAURIDINE. Cancer Res. 1963 Sep;23:1246–1259. [PubMed] [Google Scholar]
  299. PRUSOFF W. H. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta. 1959 Mar;32(1):295–296. doi: 10.1016/0006-3002(59)90597-9. [DOI] [PubMed] [Google Scholar]
  300. Page T., Connor J. D. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem. 1990;22(4):379–383. doi: 10.1016/0020-711x(90)90140-x. [DOI] [PubMed] [Google Scholar]
  301. Pahwa S., Biron K., Lim W., Swenson P., Kaplan M. H., Sadick N., Pahwa R. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA. 1988 Nov 18;260(19):2879–2882. [PubMed] [Google Scholar]
  302. Palestine A. G., Polis M. A., De Smet M. D., Baird B. F., Falloon J., Kovacs J. A., Davey R. T., Zurlo J. J., Zunich K. M., Davis M. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991 Nov 1;115(9):665–673. doi: 10.7326/0003-4819-115-9-665. [DOI] [PubMed] [Google Scholar]
  303. Parris D. S., Harrington J. E. Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother. 1982 Jul;22(1):71–77. doi: 10.1128/aac.22.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  304. Patterson J. L., Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis. 1990 Nov-Dec;12(6):1139–1146. doi: 10.1093/clinids/12.6.1139. [DOI] [PubMed] [Google Scholar]
  305. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M. J., Breslin H. J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 1990 Feb 1;343(6257):470–474. doi: 10.1038/343470a0. [DOI] [PubMed] [Google Scholar]
  306. Pazin G. J., Harger J. H., Armstrong J. A., Breinig M. K., Caplan R. J., Cantell K., Ho M. Leukocyte interferon for treating first episodes of genital herpes in women. J Infect Dis. 1987 Dec;156(6):891–898. doi: 10.1093/infdis/156.6.891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  307. Peavy D. L., Koff W. C., Hyman D. S., Knight V. Inhibition of lymphocyte proliferative responses by ribavirin. Infect Immun. 1980 Aug;29(2):583–589. doi: 10.1128/iai.29.2.583-589.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  308. Pedersen C., Sandström E., Petersen C. S., Norkrans G., Gerstoft J., Karlsson A., Christensen K. C., Håkansson C., Pehrson P. O., Nielsen J. O. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group. N Engl J Med. 1990 Jun 21;322(25):1757–1763. doi: 10.1056/NEJM199006213222501. [DOI] [PubMed] [Google Scholar]
  309. Pelling J. C., Drach J. C., Shipman C., Jr Internucleotide incorporation of arabinosyladenine into herpes simplex virus and mammalian cell DNA. Virology. 1981 Mar;109(2):323–335. doi: 10.1016/0042-6822(81)90503-1. [DOI] [PubMed] [Google Scholar]
  310. Perno C. F., Yarchoan R., Cooney D. A., Hartman N. R., Gartner S., Popovic M., Hao Z., Gerrard T. L., Wilson Y. A., Johns D. G. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med. 1988 Sep 1;168(3):1111–1125. doi: 10.1084/jem.168.3.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  311. Perno C. F., Yarchoan R., Cooney D. A., Hartman N. R., Webb D. S., Hao Z., Mitsuya H., Johns D. G., Broder S. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med. 1989 Mar 1;169(3):933–951. doi: 10.1084/jem.169.3.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  312. Perren T. J., Powles R. L., Easton D., Stolle K., Selby P. J. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med. 1988 Aug 29;85(2A):99–101. [PubMed] [Google Scholar]
  313. Perrillo R. P., Regenstein F. G., Peters M. G., DeSchryver-Kecskemeti K., Bodicky C. J., Campbell C. R., Kuhns M. C. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med. 1988 Jul 15;109(2):95–100. doi: 10.7326/0003-4819-109-2-95. [DOI] [PubMed] [Google Scholar]
  314. Perrillo R. P., Schiff E. R., Davis G. L., Bodenheimer H. C., Jr, Lindsay K., Payne J., Dienstag J. L., O'Brien C., Tamburro C., Jacobson I. M. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990 Aug 2;323(5):295–301. doi: 10.1056/NEJM199008023230503. [DOI] [PubMed] [Google Scholar]
  315. Pestka S., Langer J. A., Zoon K. C., Samuel C. E. Interferons and their actions. Annu Rev Biochem. 1987;56:727–777. doi: 10.1146/annurev.bi.56.070187.003455. [DOI] [PubMed] [Google Scholar]
  316. Peterslund N. A., Seyer-Hansen K., Ipsen J., Esmann V., Schonheyder H., Juhl H. Acyclovir in herpes zoster. Lancet. 1981 Oct 17;2(8251):827–830. doi: 10.1016/s0140-6736(81)91102-8. [DOI] [PubMed] [Google Scholar]
  317. Pizzo P. A., Butler K., Balis F., Brouwers E., Hawkins M., Eddy J., Einloth M., Falloon J., Husson R., Jarosinski P. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Pediatr. 1990 Nov;117(5):799–808. doi: 10.1016/s0022-3476(05)83348-7. [DOI] [PubMed] [Google Scholar]
  318. Pizzo P. A., Eddy J., Falloon J., Balis F. M., Murphy R. F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. doi: 10.1056/NEJM198810063191401. [DOI] [PubMed] [Google Scholar]
  319. Plotkin S. A., Starr S. E., Bryan C. K. In vitro and in vivo responses of cytomegalovirus to acyclovir. Am J Med. 1982 Jul 20;73(1A):257–261. doi: 10.1016/0002-9343(82)90101-2. [DOI] [PubMed] [Google Scholar]
  320. Pluda J. M., Yarchoan R., Jaffe E. S., Feuerstein I. M., Solomon D., Steinberg S. M., Wyvill K. M., Raubitschek A., Katz D., Broder S. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med. 1990 Aug 15;113(4):276–282. doi: 10.7326/0003-4819-113-4-276. [DOI] [PubMed] [Google Scholar]
  321. Poli G., Orenstein J. M., Kinter A., Folks T. M., Fauci A. S. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science. 1989 May 5;244(4904):575–577. doi: 10.1126/science.2470148. [DOI] [PubMed] [Google Scholar]
  322. Potter C. W., Phair J. P., Vodinelich L., Fenton R., Jennings R. Antiviral, immunosuppressive and antitumour effects of ribavirin. Nature. 1976 Feb 12;259(5543):496–497. doi: 10.1038/259496a0. [DOI] [PubMed] [Google Scholar]
  323. Powers C. N., Peavy D. L., Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob Agents Chemother. 1982 Jul;22(1):108–114. doi: 10.1128/aac.22.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  324. Prichard M. N., Prichard L. E., Baguley W. A., Nassiri M. R., Shipman C., Jr Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Antimicrob Agents Chemother. 1991 Jun;35(6):1060–1065. doi: 10.1128/aac.35.6.1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  325. Prichard M. N., Turk S. R., Coleman L. A., Engelhardt S. L., Shipman C., Jr, Drach J. C. A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J Virol Methods. 1990 Apr;28(1):101–106. doi: 10.1016/0166-0934(90)90091-s. [DOI] [PubMed] [Google Scholar]
  326. Prober C. G., Kirk L. E., Keeney R. E. Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study. J Pediatr. 1982 Oct;101(4):622–625. doi: 10.1016/s0022-3476(82)80725-7. [DOI] [PubMed] [Google Scholar]
  327. Prusiner P., Sundaralingam M. A new class of synthetic nucleoside analogues with broad-spectrum antiviral properties. Nat New Biol. 1973 Jul 25;244(134):116–118. doi: 10.1038/newbio244116a0. [DOI] [PubMed] [Google Scholar]
  328. Prusoff W. H., Mancini W. R., Lin T. S., Lee J. J., Siegel S. A., Otto M. J. Physical and biological consequences of incorporation of antiviral agents into virus DNA. Antiviral Res. 1984 Dec;4(6):303–315. doi: 10.1016/0166-3542(84)90001-9. [DOI] [PubMed] [Google Scholar]
  329. Rabalais G. P., Levin M. J., Berkowitz F. E. Rapid herpes simplex virus susceptibility testing using an enzyme-linked immunosorbent assay performed in situ on fixed virus-infected monolayers. Antimicrob Agents Chemother. 1987 Jun;31(6):946–948. doi: 10.1128/aac.31.6.946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  330. Rankin J. T., Jr, Eppes S. B., Antczak J. B., Joklik W. K. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology. 1989 Jan;168(1):147–158. doi: 10.1016/0042-6822(89)90413-3. [DOI] [PubMed] [Google Scholar]
  331. Ray C. G. Ribavirin. Ambivalence about an antiviral agent. Am J Dis Child. 1988 May;142(5):488–489. doi: 10.1001/archpedi.1988.02150050026022. [DOI] [PubMed] [Google Scholar]
  332. Reardon J. E., Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem. 1989 May 5;264(13):7405–7411. [PubMed] [Google Scholar]
  333. Redfield R. R., Birx D. L., Ketter N., Tramont E., Polonis V., Davis C., Brundage J. F., Smith G., Johnson S., Fowler A. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med. 1991 Jun 13;324(24):1677–1684. doi: 10.1056/NEJM199106133242401. [DOI] [PubMed] [Google Scholar]
  334. Reed E. C., Bowden R. A., Dandliker P. S., Lilleby K. E., Meyers J. D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988 Nov 15;109(10):783–788. doi: 10.7326/0003-4819-109-10-783. [DOI] [PubMed] [Google Scholar]
  335. Reed E. C., Wolford J. L., Kopecky K. J., Lilleby K. E., Dandliker P. S., Todaro J. L., McDonald G. B., Meyers J. D. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med. 1990 Apr 1;112(7):505–510. doi: 10.7326/0003-4819-112-7-505. [DOI] [PubMed] [Google Scholar]
  336. Reichman R. C., Badger G. J., Guinan M. E., Nahmias A. J., Keeney R. E., Davis L. G., Ashikaga T., Dolin R. Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Infect Dis. 1983 Feb;147(2):336–340. doi: 10.1093/infdis/147.2.336. [DOI] [PubMed] [Google Scholar]
  337. Reichman R. C., Badger G. J., Mertz G. J., Corey L., Richman D. D., Connor J. D., Redfield D., Savoia M. C., Oxman M. N., Bryson Y. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA. 1984 Apr 27;251(16):2103–2107. [PubMed] [Google Scholar]
  338. Reichman R. C., Oakes D., Bonnez W., Greisberger C., Tyring S., Miller L., Whitley R., Carveth H., Weidner M., Krueger G. Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial. Ann Intern Med. 1988 May;108(5):675–679. doi: 10.7326/0003-4819-108-5-675. [DOI] [PubMed] [Google Scholar]
  339. Renault P. F., Hoofnagle J. H., Park Y., Mullen K. D., Peters M., Jones D. B., Rustgi V., Jones E. A. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987 Sep;147(9):1577–1580. [PubMed] [Google Scholar]
  340. Resnick L., Herbst J. S., Ablashi D. V., Atherton S., Frank B., Rosen L., Horwitz S. N. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA. 1988 Jan 15;259(3):384–388. [PubMed] [Google Scholar]
  341. Reuman P. D., Bernstein D. I., Keefer M. C., Young E. C., Sherwood J. R., Schiff G. M. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 1989 Feb;11(1):27–40. doi: 10.1016/0166-3542(89)90018-1. [DOI] [PubMed] [Google Scholar]
  342. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  343. Richman D. D., Grimes J. M., Lagakos S. W. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3(8):743–746. [PubMed] [Google Scholar]
  344. Richman D. D., Hostetler K. Y., Yazaki P. J., Clark S. Fate of influenza A virion proteins after entry into subcellular fractions of LLC cells and the effect of amantadine. Virology. 1986 Jun;151(2):200–210. doi: 10.1016/0042-6822(86)90042-5. [DOI] [PubMed] [Google Scholar]
  345. Ringdén O., Lönnqvist B., Paulin T., Ahlmén J., Klintmalm G., Wahren B., Lernestedt J. O. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother. 1986 Mar;17(3):373–387. doi: 10.1093/jac/17.3.373. [DOI] [PubMed] [Google Scholar]
  346. Roberts N. A., Martin J. A., Kinchington D., Broadhurst A. V., Craig J. C., Duncan I. B., Galpin S. A., Handa B. K., Kay J., Kröhn A. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990 Apr 20;248(4953):358–361. doi: 10.1126/science.2183354. [DOI] [PubMed] [Google Scholar]
  347. Roberts R. B., Dickinson G. M., Heseltine P. N., Leedom J. M., Mansell P. W., Rodriguez S., Johnson K. M., Lubina J. A., Makuch R. W. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. J Acquir Immune Defic Syndr. 1990;3(9):884–892. [PubMed] [Google Scholar]
  348. Roberts R. B., Hollinger F. B., Parks W. P., Rasheed S., Laurence J., Heseltine P. N., Makuch R. W., Lubina J. A., Johnson K. M. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group. AIDS. 1990 Jan;4(1):67–72. doi: 10.1097/00002030-199001000-00009. [DOI] [PubMed] [Google Scholar]
  349. Roberts R. B., Jurica K., Meyer W. A., 3rd, Paxton H., Makuch R. W. A phase 1 study of ribavirin in human immunodeficiency virus-infected patients. J Infect Dis. 1990 Sep;162(3):638–642. doi: 10.1093/infdis/162.3.638. [DOI] [PubMed] [Google Scholar]
  350. Roberts R. B., Laskin O. L., Laurence J., Scavuzzo D., Murray H. W., Kim Y. T., Connor J. D. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1987 Oct;42(4):365–373. doi: 10.1038/clpt.1987.165. [DOI] [PubMed] [Google Scholar]
  351. Rodriguez W. J., Kim H. W., Brandt C. D., Fink R. J., Getson P. R., Arrobio J., Murphy T. M., McCarthy V., Parrott R. H. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J. 1987 Feb;6(2):159–163. doi: 10.1097/00006454-198702000-00004. [DOI] [PubMed] [Google Scholar]
  352. Roilides E., Venzon D., Pizzo P. A., Rubin M. Effects of antiretroviral dideoxynucleosides on polymorphonuclear leukocyte function. Antimicrob Agents Chemother. 1990 Sep;34(9):1672–1677. doi: 10.1128/aac.34.9.1672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  353. Rooke R., Tremblay M., Soudeyns H., DeStephano L., Yao X. J., Fanning M., Montaner J. S., O'Shaughnessy M., Gelmon K., Tsoukas C. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 1989 Jul;3(7):411–415. doi: 10.1097/00002030-198907000-00001. [DOI] [PubMed] [Google Scholar]
  354. Rooney J. F., Felser J. M., Ostrove J. M., Straus S. E. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med. 1986 Jun 12;314(24):1561–1564. doi: 10.1056/NEJM198606123142407. [DOI] [PubMed] [Google Scholar]
  355. Rose K. M., Jacob S. T. Selective inhibition of RNA polyadenylation by Ara-ATP in vitro: a possible mechanism for antiviral action of Ara-A. Biochem Biophys Res Commun. 1978 Apr 28;81(4):1418–1424. doi: 10.1016/0006-291x(78)91294-9. [DOI] [PubMed] [Google Scholar]
  356. Ross A. H., Julia A., Balakrishnan C. Toxicity of adenine arabinoside in humans. J Infect Dis. 1976 Jun;133 (Suppl):A192–A198. doi: 10.1093/infdis/133.supplement_2.a192. [DOI] [PubMed] [Google Scholar]
  357. Rossmann M. G. Antiviral agents targeted to interact with viral capsid proteins and a possible application to human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4625–4627. doi: 10.1073/pnas.85.13.4625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  358. Rossmann M. G., Arnold E., Erickson J. W., Frankenberger E. A., Griffith J. P., Hecht H. J., Johnson J. E., Kamer G., Luo M., Mosser A. G. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985 Sep 12;317(6033):145–153. doi: 10.1038/317145a0. [DOI] [PubMed] [Google Scholar]
  359. Rothenberg M., Johnson G., Laughlin C., Green I., Cradock J., Sarver N., Cohen J. S. Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications. J Natl Cancer Inst. 1989 Oct 18;81(20):1539–1544. doi: 10.1093/jnci/81.20.1539. [DOI] [PubMed] [Google Scholar]
  360. Sacks S. L., Merigan T. C., Kaminska J., Fox I. H. Inactivation of S-adenosylhomocysteine hydrolase during adenine arabinoside therapy. J Clin Invest. 1982 Jan;69(1):226–230. doi: 10.1172/JCI110434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  361. Sacks S. L., Wanklin R. J., Reece D. E., Hicks K. A., Tyler K. L., Coen D. M. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med. 1989 Dec 1;111(11):893–899. doi: 10.7326/0003-4819-111-11-893. [DOI] [PubMed] [Google Scholar]
  362. Safrin S., Assaykeen T., Follansbee S., Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis. 1990 Jun;161(6):1078–1084. doi: 10.1093/infdis/161.6.1078. [DOI] [PubMed] [Google Scholar]
  363. Safrin S., Berger T. G., Gilson I., Wolfe P. R., Wofsy C. B., Mills J., Biron K. K. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991 Jul 1;115(1):19–21. doi: 10.7326/0003-4819-115-1-19. [DOI] [PubMed] [Google Scholar]
  364. Safrin S., Crumpacker C., Chatis P., Davis R., Hafner R., Rush J., Kessler H. A., Landry B., Mills J. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1991 Aug 22;325(8):551–555. doi: 10.1056/NEJM199108223250805. [DOI] [PubMed] [Google Scholar]
  365. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature. 1987 Jun 11;327(6122):473–476. doi: 10.1038/327473a0. [DOI] [PubMed] [Google Scholar]
  366. Sandstrom E. G., Kaplan J. C., Byington R. E., Hirsch M. S. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet. 1985 Jun 29;1(8444):1480–1482. doi: 10.1016/s0140-6736(85)92255-x. [DOI] [PubMed] [Google Scholar]
  367. Saral R., Ambinder R. F., Burns W. H., Angelopulos C. M., Griffin D. E., Burke P. J., Lietman P. S. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1983 Dec;99(6):773–776. doi: 10.7326/0003-4819-99-6-773. [DOI] [PubMed] [Google Scholar]
  368. Saral R., Burns W. H., Laskin O. L., Santos G. W., Lietman P. S. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981 Jul 9;305(2):63–67. doi: 10.1056/NEJM198107093050202. [DOI] [PubMed] [Google Scholar]
  369. Sawyer M. H., Webb D. E., Balow J. E., Straus S. E. Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988 Jun;84(6):1067–1071. doi: 10.1016/0002-9343(88)90313-0. [DOI] [PubMed] [Google Scholar]
  370. Scadden D. T., Bering H. A., Levine J. D., Bresnahan J., Evans L., Epstein C., Groopman J. E. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol. 1991 May;9(5):802–808. doi: 10.1200/JCO.1991.9.5.802. [DOI] [PubMed] [Google Scholar]
  371. Schabel F. M., Jr The antiviral activity of 9-beta-D-arabinofuranosyladenine (ARA-A). Chemotherapy. 1968;13(6):321–338. doi: 10.1159/000220567. [DOI] [PubMed] [Google Scholar]
  372. Schaeffer H. J., Beauchamp L., de Miranda P., Elion G. B., Bauer D. J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978 Apr 13;272(5654):583–585. doi: 10.1038/272583a0. [DOI] [PubMed] [Google Scholar]
  373. Schmidt G. M., Horak D. A., Niland J. C., Duncan S. R., Forman S. J., Zaia J. A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991 Apr 11;324(15):1005–1011. doi: 10.1056/NEJM199104113241501. [DOI] [PubMed] [Google Scholar]
  374. Schmitt F. A., Bigley J. W., McKinnis R., Logue P. E., Evans R. W., Drucker J. L. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988 Dec 15;319(24):1573–1578. doi: 10.1056/NEJM198812153192404. [DOI] [PubMed] [Google Scholar]
  375. Schnipper L. E., Crumpacker C. S. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2270–2273. doi: 10.1073/pnas.77.4.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  376. Schooley R. T., Merigan T. C., Gaut P., Hirsch M. S., Holodniy M., Flynn T., Liu S., Byington R. E., Henochowicz S., Gubish E. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med. 1990 Feb 15;112(4):247–253. doi: 10.7326/0003-4819-112-4-247. [DOI] [PubMed] [Google Scholar]
  377. Schulman K. A., Lynn L. A., Glick H. A., Eisenberg J. M. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 May 1;114(9):798–802. doi: 10.7326/0003-4819-114-9-798. [DOI] [PubMed] [Google Scholar]
  378. Schwartz D. H., Skowron G., Merigan T. C. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1991;4(1):11–23. [PubMed] [Google Scholar]
  379. Schwartz P. M., Shipman C., Jr, Drach J. C. Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus-infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in the presence of an adenosine deaminase inhibitor. Antimicrob Agents Chemother. 1976 Jul;10(1):64–74. doi: 10.1128/aac.10.1.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  380. Seale L., Jones C. J., Kathpalia S., Jackson G. G., Mozes M., Maddux M. S., Packham D. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA. 1985 Dec 27;254(24):3435–3438. [PubMed] [Google Scholar]
  381. Sears S. D., Clements M. L. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother. 1987 Oct;31(10):1470–1473. doi: 10.1128/aac.31.10.1470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  382. Seeff L. B., Wright E. C., Zimmerman H. J., Alter H. J., Dietz A. A., Felsher B. F., Finkelstein J. D., Garcia-Pont P., Gerin J. L., Greenlee H. B. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med. 1978 Mar;88(3):285–293. doi: 10.7326/0003-4819-88-3-285. [DOI] [PubMed] [Google Scholar]
  383. Selby P. J., Powles R. L., Easton D., Perren T. J., Stolle K., Jameson B., Fiddian A. P., Tryhorn Y., Stern H. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer. 1989 Mar;59(3):434–438. doi: 10.1038/bjc.1989.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  384. Shepp D. H., Dandliker P. S., Flournoy N., Meyers J. D. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation. 1987 May;43(5):654–658. doi: 10.1097/00007890-198705000-00010. [DOI] [PubMed] [Google Scholar]
  385. Shepp D. H., Dandliker P. S., Meyers J. D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med. 1986 Jan 23;314(4):208–212. doi: 10.1056/NEJM198601233140404. [DOI] [PubMed] [Google Scholar]
  386. Shepp D. H., Dandliker P. S., de Miranda P., Burnette T. C., Cederberg D. M., Kirk L. E., Meyers J. D. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985 Sep;103(3):368–373. doi: 10.7326/0003-4819-103-3-368. [DOI] [PubMed] [Google Scholar]
  387. Shepp D. H., Newton B. A., Dandliker P. S., Flournoy N., Meyers J. D. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann Intern Med. 1985 Jun;102(6):783–785. doi: 10.7326/0003-4819-102-6-783. [DOI] [PubMed] [Google Scholar]
  388. Shigeta S., Mori S., Yokota T., Konno K., De Clercq E. Characterization of a varicella-zoster virus variant with altered thymidine kinase activity. Antimicrob Agents Chemother. 1986 Jun;29(6):1053–1058. doi: 10.1128/aac.29.6.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  389. Shindo M., Di Bisceglie A. M., Cheung L., Shih J. W., Cristiano K., Feinstone S. M., Hoofnagle J. H. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991 Nov 1;115(9):700–704. doi: 10.7326/0003-4819-115-9-700. [DOI] [PubMed] [Google Scholar]
  390. Sibrack C. D., Gutman L. T., Wilfert C. M., McLaren C., St Clair M. H., Keller P. M., Barry D. W. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis. 1982 Nov;146(5):673–682. doi: 10.1093/infdis/146.5.673. [DOI] [PubMed] [Google Scholar]
  391. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(4050):705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
  392. Silvestris F., Gernone A., Frassanito M. A., Dammacco F. Immunologic effects of long-term thymopentin treatment in patients with HIV-induced lymphadenopathy syndrome. J Lab Clin Med. 1989 Feb;113(2):139–144. [PubMed] [Google Scholar]
  393. Sjövall J., Bergdahl S., Movin G., Ogenstad S., Saarimäki M. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1989 Jul;33(7):1023–1031. doi: 10.1128/aac.33.7.1023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  394. Sjövall J., Karlsson A., Ogenstad S., Sandström E., Saarimäki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther. 1988 Jul;44(1):65–73. doi: 10.1038/clpt.1988.114. [DOI] [PubMed] [Google Scholar]
  395. Skowron G., Merigan T. C. Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Am J Med. 1990 May 21;88(5B):20S–23S. doi: 10.1016/0002-9343(90)90417-c. [DOI] [PubMed] [Google Scholar]
  396. Sköldenberg B., Forsgren M., Alestig K., Bergström T., Burman L., Dahlqvist E., Forkman A., Frydén A., Lövgren K., Norlin K. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet. 1984 Sep 29;2(8405):707–711. doi: 10.1016/s0140-6736(84)92623-0. [DOI] [PubMed] [Google Scholar]
  397. Smee D. F., Martin J. C., Verheyden J. P., Matthews T. R. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1983 May;23(5):676–682. doi: 10.1128/aac.23.5.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  398. Smee D. F., Matthews T. R. Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells. Antimicrob Agents Chemother. 1986 Jul;30(1):117–121. doi: 10.1128/aac.30.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  399. Smith D. H., Byrn R. A., Marsters S. A., Gregory T., Groopman J. E., Capon D. J. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science. 1987 Dec 18;238(4834):1704–1707. doi: 10.1126/science.3500514. [DOI] [PubMed] [Google Scholar]
  400. Smith D. W., Frankel L. R., Mathers L. H., Tang A. T., Ariagno R. L., Prober C. G. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991 Jul 4;325(1):24–29. doi: 10.1056/NEJM199107043250105. [DOI] [PubMed] [Google Scholar]
  401. Smith T. J., Kremer M. J., Luo M., Vriend G., Arnold E., Kamer G., Rossmann M. G., McKinlay M. A., Diana G. D., Otto M. J. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science. 1986 Sep 19;233(4770):1286–1293. doi: 10.1126/science.3018924. [DOI] [PubMed] [Google Scholar]
  402. Snydman D. R., Werner B. G., Heinze-Lacey B., Berardi V. P., Tilney N. L., Kirkman R. L., Milford E. L., Cho S. I., Bush H. L., Jr, Levey A. S. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987 Oct 22;317(17):1049–1054. doi: 10.1056/NEJM198710223171703. [DOI] [PubMed] [Google Scholar]
  403. Sommadossi J. P., Bevan R., Ling T., Lee F., Mastre B., Chaplin M. D., Nerenberg C., Koretz S., Buhles W. C., Jr Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 3):S507–S514. doi: 10.1093/clinids/10.supplement_3.s507. [DOI] [PubMed] [Google Scholar]
  404. Sommadossi J. P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987 Mar;31(3):452–454. doi: 10.1128/aac.31.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  405. Sonnenblick M., Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 1991 Mar;99(3):557–561. doi: 10.1378/chest.99.3.557. [DOI] [PubMed] [Google Scholar]
  406. Spear J. B., Benson C. A., Pottage J. C., Jr, Paul D. A., Landay A. L., Kessler H. A. Rapid rebound of serum human immunodeficiency virus antigen after discontinuing zidovudine therapy. J Infect Dis. 1988 Nov;158(5):1132–1133. doi: 10.1093/infdis/158.5.1132. [DOI] [PubMed] [Google Scholar]
  407. Spiegel R. J., Spicehandler J. R., Jacobs S. L., Oden E. M. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med. 1986 Feb;80(2):223–228. doi: 10.1016/0002-9343(86)90013-6. [DOI] [PubMed] [Google Scholar]
  408. Spruance S. L., Freeman D. J., Stewart J. C., McKeough M. B., Wenerstrom L. G., Krueger G. G., Piepkorn M. W., Stroop W. G., Rowe N. H. The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. J Infect Dis. 1991 Apr;163(4):728–734. doi: 10.1093/infdis/163.4.728. [DOI] [PubMed] [Google Scholar]
  409. Spruance S. L., Hamill M. L., Hoge W. S., Davis L. G., Mills J. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA. 1988 Sep 16;260(11):1597–1599. [PubMed] [Google Scholar]
  410. Spruance S. L., Stewart J. C., Freeman D. J., Brightman V. J., Cox J. L., Wenerstrom G., McKeough M. B., Rowe N. H. Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: a multicenter placebo-controlled trial. J Infect Dis. 1990 Feb;161(2):191–197. doi: 10.1093/infdis/161.2.191. [DOI] [PubMed] [Google Scholar]
  411. Spruance S. L., Stewart J. C., Rowe N. H., McKeough M. B., Wenerstrom G., Freeman D. J. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis. 1990 Feb;161(2):185–190. doi: 10.1093/infdis/161.2.185. [DOI] [PubMed] [Google Scholar]
  412. St Clair M. H., Furman P. A., Lubbers C. M., Elion G. B. Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother. 1980 Nov;18(5):741–745. doi: 10.1128/aac.18.5.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  413. St Clair M. H., Richards C. A., Spector T., Weinhold K. J., Miller W. H., Langlois A. J., Furman P. A. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother. 1987 Dec;31(12):1972–1977. doi: 10.1128/aac.31.12.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  414. Stanat S. C., Reardon J. E., Erice A., Jordan M. C., Drew W. L., Biron K. K. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother. 1991 Nov;35(11):2191–2197. doi: 10.1128/aac.35.11.2191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  415. Steele R. W., Charlton R. K. Immune modulators as antiviral agents. Clin Lab Med. 1987 Dec;7(4):911–924. [PubMed] [Google Scholar]
  416. Stevens J. G. Human herpesviruses: a consideration of the latent state. Microbiol Rev. 1989 Sep;53(3):318–332. doi: 10.1128/mr.53.3.318-332.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  417. Straus S. E., Seidlin M., Takiff H. E., Rooney J. F., Felser J. M., Smith H. A., Roane P., Johnson F., Hallahan C., Ostrove J. M. Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpes. Sex Transm Dis. 1989 Apr-Jun;16(2):107–113. doi: 10.1097/00007435-198904000-00013. [DOI] [PubMed] [Google Scholar]
  418. Streeter D. G., Witkowski J. T., Khare G. P., Sidwell R. W., Bauer R. J., Robins R. K., Simon L. N. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174–1178. doi: 10.1073/pnas.70.4.1174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  419. Stridh S. Determination of ribonucleoside triphosphate pools in influenza A virus-infected MDCK cells. Arch Virol. 1983;77(2-4):223–229. doi: 10.1007/BF01309269. [DOI] [PubMed] [Google Scholar]
  420. Sugrue R. J., Bahadur G., Zambon M. C., Hall-Smith M., Douglas A. R., Hay A. J. Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO J. 1990 Nov;9(11):3469–3476. doi: 10.1002/j.1460-2075.1990.tb07555.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  421. Sullivan K. M., Kopecky K. J., Jocom J., Fisher L., Buckner C. D., Meyers J. D., Counts G. W., Bowden R. A., Peterson F. B., Witherspoon R. P. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990 Sep 13;323(11):705–712. doi: 10.1056/NEJM199009133231103. [DOI] [PubMed] [Google Scholar]
  422. Sweet C., Hayden F. G., Jakeman K. J., Grambas S., Hay A. J. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis. 1991 Nov;164(5):969–972. doi: 10.1093/infdis/164.5.969. [DOI] [PubMed] [Google Scholar]
  423. Swierkosz E. M., Scholl D. R., Brown J. L., Jollick J. D., Gleaves C. A. Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus. Antimicrob Agents Chemother. 1987 Oct;31(10):1465–1469. doi: 10.1128/aac.31.10.1465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  424. Szoka F. C., Jr, Chu C. J. Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes. Antimicrob Agents Chemother. 1988 Jun;32(6):858–864. doi: 10.1128/aac.32.6.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  425. Taber L. H., Knight V., Gilbert B. E., McClung H. W., Wilson S. Z., Norton H. J., Thurson J. M., Gordon W. H., Atmar R. L., Schlaudt W. R. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 1983 Nov;72(5):613–618. [PubMed] [Google Scholar]
  426. Telenti A., Smith T. F. Screening with a shell vial assay for antiviral activity against cytomegalovirus. Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):5–8. doi: 10.1016/0732-8893(89)90036-9. [DOI] [PubMed] [Google Scholar]
  427. Tenser R. B., Edris W. A. Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus after in vivo complementation. J Virol. 1987 Jul;61(7):2171–2174. doi: 10.1128/jvi.61.7.2171-2174.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  428. Thin R. N., Nabarro J. M., Parker J. D., Fiddian A. P. Topical acyclovir in the treatment of initial genital herpes. Br J Vener Dis. 1983 Apr;59(2):116–119. doi: 10.1136/sti.59.2.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  429. Till M. A., Ghetie V., Gregory T., Patzer E. J., Porter J. P., Uhr J. W., Capon D. J., Vitetta E. S. HIV-infected cells are killed by rCD4-ricin A chain. Science. 1988 Nov 25;242(4882):1166–1168. doi: 10.1126/science.2847316. [DOI] [PubMed] [Google Scholar]
  430. Tocci M. J., Livelli T. J., Perry H. C., Crumpacker C. S., Field A. K. Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication. Antimicrob Agents Chemother. 1984 Feb;25(2):247–252. doi: 10.1128/aac.25.2.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  431. Togo Y., Hornick R. B., Felitti V. J., Kaufman M. L., Dawkins A. T., Jr, Kilpe V. E., Claghorn J. L. Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza. JAMA. 1970 Feb 16;211(7):1149–1156. [PubMed] [Google Scholar]
  432. Toltzis P., Marx C. M., Kleinman N., Levine E. M., Schmidt E. V. Zidovudine-associated embryonic toxicity in mice. J Infect Dis. 1991 Jun;163(6):1212–1218. doi: 10.1093/infdis/163.6.1212. [DOI] [PubMed] [Google Scholar]
  433. Toltzis P., O'Connell K., Patterson J. L. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob Agents Chemother. 1988 Apr;32(4):492–497. doi: 10.1128/aac.32.4.492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  434. Traunecker A., Schneider J., Kiefer H., Karjalainen K. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature. 1989 May 4;339(6219):68–70. doi: 10.1038/339068a0. [DOI] [PubMed] [Google Scholar]
  435. Tucker W. E., Jr Preclinical toxicology profile of acyclovir: an overview. Am J Med. 1982 Jul 20;73(1A):27–30. doi: 10.1016/0002-9343(82)90058-4. [DOI] [PubMed] [Google Scholar]
  436. Van Der Pijl J. W., Frissen P. H., Reiss P., Hulsebosch H. J., Van Den Tweel J. G., Lange J. M., Danner S. A. Foscarnet and penile ulceration. Lancet. 1990 Feb 3;335(8684):286–286. doi: 10.1016/0140-6736(90)90100-j. [DOI] [PubMed] [Google Scholar]
  437. Van Voris L. P., Betts R. F., Hayden F. G., Christmas W. A., Douglas R. G., Jr Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 1981 Mar 20;245(11):1128–1131. doi: 10.1001/jama.245.11.1128. [DOI] [PubMed] [Google Scholar]
  438. Vance J. C., Davis D. Interferon alpha-2b injections used as an adjuvant therapy to carbon dioxide laser vaporization of recalcitrant ano-genital condylomata acuminata. J Invest Dermatol. 1990 Dec;95(6 Suppl):146S–148S. doi: 10.1111/1523-1747.ep12875118. [DOI] [PubMed] [Google Scholar]
  439. Vere Hodge R. A., Sutton D., Boyd M. R., Harnden M. R., Jarvest R. L. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother. 1989 Oct;33(10):1765–1773. doi: 10.1128/aac.33.10.1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  440. Vogt M. W., Hartshorn K. L., Furman P. A., Chou T. C., Fyfe J. A., Coleman L. A., Crumpacker C., Schooley R. T., Hirsch M. S. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science. 1987 Mar 13;235(4794):1376–1379. doi: 10.1126/science.2435003. [DOI] [PubMed] [Google Scholar]
  441. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]
  442. Vrang L., Oberg B. PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase. Antimicrob Agents Chemother. 1986 May;29(5):867–872. doi: 10.1128/aac.29.5.867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  443. Wade J. C., McGuffin R. W., Springmeyer S. C., Newton B., Singer J. W., Meyers J. D. Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon. J Infect Dis. 1983 Sep;148(3):557–562. doi: 10.1093/infdis/148.3.557. [DOI] [PubMed] [Google Scholar]
  444. Wade J. C., McLaren C., Meyers J. D. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis. 1983 Dec;148(6):1077–1082. doi: 10.1093/infdis/148.6.1077. [DOI] [PubMed] [Google Scholar]
  445. Wade J. C., Meyers J. D. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med. 1983 Jun;98(6):921–925. doi: 10.7326/0003-4819-98-6-921. [DOI] [PubMed] [Google Scholar]
  446. Wade J. C., Newton B., Flournoy N., Meyers J. D. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984 Jun;100(6):823–828. doi: 10.7326/0003-4819-100-6-823. [DOI] [PubMed] [Google Scholar]
  447. Wahren B., Oberg B. Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology. 1980;14(1):7–15. doi: 10.1159/000149156. [DOI] [PubMed] [Google Scholar]
  448. Wald E. R., Dashefsky B., Green M. In re ribavirin: a case of premature adjudication? J Pediatr. 1988 Jan;112(1):154–158. doi: 10.1016/s0022-3476(88)80143-4. [DOI] [PubMed] [Google Scholar]
  449. Walmsley S. L., Chew E., Read S. E., Vellend H., Salit I., Rachlis A., Fanning M. M. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet). J Infect Dis. 1988 Mar;157(3):569–572. doi: 10.1093/infdis/157.3.569. [DOI] [PubMed] [Google Scholar]
  450. Waqar M. A., Evans M. J., Manly K. F., Hughes R. G., Huberman J. A. Effects of 2',3'-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol. 1984 Nov;121(2):402–408. doi: 10.1002/jcp.1041210218. [DOI] [PubMed] [Google Scholar]
  451. Watts D. H., Brown Z. A., Tartaglione T., Burchett S. K., Opheim K., Coombs R., Corey L. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991 Feb;163(2):226–232. doi: 10.1093/infdis/163.2.226. [DOI] [PubMed] [Google Scholar]
  452. Weis W., Brown J. H., Cusack S., Paulson J. C., Skehel J. J., Wiley D. C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988 Jun 2;333(6172):426–431. doi: 10.1038/333426a0. [DOI] [PubMed] [Google Scholar]
  453. Weisbart R. H., Gasson J. C., Golde D. W. Colony-stimulating factors and host defense. Ann Intern Med. 1989 Feb 15;110(4):297–303. doi: 10.7326/0003-4819-110-4-297. [DOI] [PubMed] [Google Scholar]
  454. Whitley R. J., Alford C. A., Hirsch M. S., Schooley R. T., Luby J. P., Aoki F. Y., Hanley D., Nahmias A. J., Soong S. J. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986 Jan 16;314(3):144–149. doi: 10.1056/NEJM198601163140303. [DOI] [PubMed] [Google Scholar]
  455. Whitley R. J., Ch'ien L. T., Dolin R., Galasso G. J., Alford C. A., Jr Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med. 1976 May 27;294(22):1193–1199. doi: 10.1056/NEJM197605272942201. [DOI] [PubMed] [Google Scholar]
  456. Whitley R. J., Levin M., Barton N., Hershey B. J., Davis G., Keeney R. E., Whelchel J., Diethelm A. G., Kartus P., Soong S. J. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Infect Dis. 1984 Sep;150(3):323–329. doi: 10.1093/infdis/150.3.323. [DOI] [PubMed] [Google Scholar]
  457. Whitley R. J., Nahmias A. J., Soong S. J., Galasso G. G., Fleming C. L., Alford C. A. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics. 1980 Oct;66(4):495–501. [PubMed] [Google Scholar]
  458. Whitley R. J., Soong S. J., Dolin R., Galasso G. J., Ch'ien L. T., Alford C. A. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med. 1977 Aug 11;297(6):289–294. doi: 10.1056/NEJM197708112970601. [DOI] [PubMed] [Google Scholar]
  459. Whitley R. J., Soong S. J., Hirsch M. S., Karchmer A. W., Dolin R., Galasso G., Dunnick J. K., Alford C. A. Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med. 1981 Feb 5;304(6):313–318. doi: 10.1056/NEJM198102053040602. [DOI] [PubMed] [Google Scholar]
  460. Whitley R. J., Yeager A., Kartus P., Bryson Y., Connor J. D., Alford C. A., Nahmias A., Soong S. J. Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics. 1983 Dec;72(6):778–785. [PubMed] [Google Scholar]
  461. Whitley R., Arvin A., Prober C., Burchett S., Corey L., Powell D., Plotkin S., Starr S., Alford C., Connor J. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14;324(7):444–449. doi: 10.1056/NEJM199102143240703. [DOI] [PubMed] [Google Scholar]
  462. Whitley R., Hilty M., Haynes R., Bryson Y., Connor J. D., Soong S. J., Alford C. A. Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr. 1982 Jul;101(1):125–131. doi: 10.1016/s0022-3476(82)80201-1. [DOI] [PubMed] [Google Scholar]
  463. Wills R. J. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990 Nov;19(5):390–399. doi: 10.2165/00003088-199019050-00003. [DOI] [PubMed] [Google Scholar]
  464. Wilson S. Z., Gilbert B. E., Quarles J. M., Knight V., McClung H. W., Moore R. V., Couch R. B. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother. 1984 Aug;26(2):200–203. doi: 10.1128/aac.26.2.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  465. Wingfield W. L., Pollack D., Grunert R. R. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med. 1969 Sep 11;281(11):579–584. doi: 10.1056/NEJM196909112811102. [DOI] [PubMed] [Google Scholar]
  466. Winston D. J., Eron L. J., Ho M., Pazin G., Kessler H., Pottage J. C., Jr, Gallagher J., Sartiano G., Ho W. G., Champlin R. E. Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am J Med. 1988 Aug;85(2):147–151. doi: 10.1016/s0002-9343(88)80333-4. [DOI] [PubMed] [Google Scholar]
  467. Winston D. J., Ho W. G., Lin C. H., Bartoni K., Budinger M. D., Gale R. P., Champlin R. E. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987 Jan;106(1):12–18. doi: 10.7326/0003-4819-106-1-12. [DOI] [PubMed] [Google Scholar]
  468. Witkowski J. T., Robins R. K., Sidwell R. W., Simon L. N. Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem. 1972 Nov;15(11):1150–1154. doi: 10.1021/jm00281a014. [DOI] [PubMed] [Google Scholar]
  469. Woodson R. D., Clinton J. J. Hepatitis prophylaxis abroad. Effectiveness of immune serum globulin in protecting Peace Corps volunteers. JAMA. 1969 Aug 18;209(7):1053–1058. doi: 10.1001/jama.209.7.1053. [DOI] [PubMed] [Google Scholar]
  470. Wray S. K., Gilbert B. E., Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 1985 Feb;5(1):39–48. doi: 10.1016/0166-3542(85)90013-0. [DOI] [PubMed] [Google Scholar]
  471. Wray S. K., Gilbert B. E., Noall M. W., Knight V. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res. 1985 Feb;5(1):29–37. doi: 10.1016/0166-3542(85)90012-9. [DOI] [PubMed] [Google Scholar]
  472. Yarchoan R., Berg G., Brouwers P., Fischl M. A., Spitzer A. R., Wichman A., Grafman J., Thomas R. V., Safai B., Brunetti A. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1987 Jan 17;1(8525):132–135. doi: 10.1016/s0140-6736(87)91968-4. [DOI] [PubMed] [Google Scholar]
  473. Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989 Sep 14;321(11):726–738. doi: 10.1056/NEJM198909143211106. [DOI] [PubMed] [Google Scholar]
  474. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]
  475. Yarchoan R., Pluda J. M., Thomas R. V., Mitsuya H., Brouwers P., Wyvill K. M., Hartman N., Johns D. G., Broder S. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet. 1990 Sep 1;336(8714):526–529. doi: 10.1016/0140-6736(90)92085-v. [DOI] [PubMed] [Google Scholar]
  476. Yarchoan R., Thomas R. V., Grafman J., Wichman A., Dalakas M., McAtee N., Berg G., Fischl M., Perno C. F., Klecker R. W. Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease. Ann Neurol. 1988;23 (Suppl):S82–S87. doi: 10.1002/ana.410230722. [DOI] [PubMed] [Google Scholar]
  477. Younkin S. W., Betts R. F., Roth F. K., Douglas R. G., Jr Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother. 1983 Apr;23(4):577–582. doi: 10.1128/aac.23.4.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  478. Zamecnik P. C., Stephenson M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978 Jan;75(1):280–284. doi: 10.1073/pnas.75.1.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  479. Zebedee S. L., Lamb R. A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol. 1988 Aug;62(8):2762–2772. doi: 10.1128/jvi.62.8.2762-2772.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  480. Zhu Z., Schinazi R. F., Chu C. K., Williams G. J., Colby C. B., Sommadossi J. P. Cellular metabolism of 3'-azido-2',3'-dideoxyuridine with formation of 5'-O-diphosphohexose derivatives by previously unrecognized metabolic pathways for 2'-deoxyuridine analogs. Mol Pharmacol. 1990 Dec;38(6):929–938. [PubMed] [Google Scholar]
  481. de Miranda P., Blum M. R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):29–37. doi: 10.1093/jac/12.suppl_b.29. [DOI] [PubMed] [Google Scholar]
  482. de Wit R., Schattenkerk J. K., Boucher C. A., Bakker P. J., Veenhof K. H., Danner S. A. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1214–1217. doi: 10.1016/s0140-6736(88)90810-0. [DOI] [PubMed] [Google Scholar]
  483. van der Horst C., Joncas J., Ahronheim G., Gustafson N., Stein G., Gurwith M., Fleisher G., Sullivan J., Sixbey J., Roland S. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis. 1991 Oct;164(4):788–792. doi: 10.1093/infdis/164.4.788. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES